Stockwinners Market Radar for January 19, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:45 EST Alphatec CEO sells $2.38M in common stock - In a regulatory filing, Alphatec disclosed that its CEO Patrick Miles sold 180K shares of common stock on January 17th in a total transaction size of $2.38M.

20:07 EST Keurig Dr Pepper CFO buys $350K in common stock - In a regulatory filing, Keurig Dr Pepper disclosed that its CFO Sudhanshu Priyadarshi bought 10K shares of common stock on January 18th in a total transaction size of $350K.

20:04 EST Cathie Wood's ARK Investment bought 158.2K shares of Compass Pathways today

20:02 EST Cathie Wood's ARK Investment bought 724.8K shares of Invitae today

19:10 EST AbCellera announces U.S. Patent Office appeal board upholds patent - The company states: "AbCellera announced that the United States Patent and Trademark Office's Patent Trial and Appeal Board has ruled in favor of AbCellera in an Inter Partes Review filed by Berkeley Lights that challenged AbCellera's U.S. Patent No. 10,087,408. AbCellera's '408 Patent is directed to microfluidic devices and using such devices to culture cells, monitor a response, and recover selected cells. The IPR proceeding stems from AbCellera and the University of British Columbia (UBC) suing Berkeley Lights for patent infringement currently pending in the United States District Court for the Northern District of California. In response to AbCellera's infringement claims, Berkeley Lights filed three separate petitions with the PTAB seeking to invalidate multiple patents. The PTAB previously rejected two of Berkeley Lights' petitions, disagreeing that certain challenged claims were invalid. Berkeley Lights challenged the claims of the '408 Patent alleging invalidity based on anticipation and obviousness over the prior art. In response to claims against the '408 patent, AbCellera and UBC opposed institution and after oral argument, the PTAB rejected all of Berkeley Lights' arguments and confirmed that all claims of AbCellera's '408 Patent are valid."

18:38 EST Netflix not commenting on interest in buying WWE - Says still hasn't figured out how to deliver profits from sports rights in current model.

18:34 EST Netflix to eye opportunities to raise prices - Says password crackdown won't be popular with members. Says there will be some members unhappy with password crackdown.

18:25 EST Netflix sees advertising growing to at least $3B-$4B - Says not seeing many users downgrade to ad tier. Says take rate and growth on ad-tier is solid. Says engagement from ad-tier users comparable to users on non-ad plan. Says expects to beat Hulu in ad business in several years.

18:03 EST Eli Lilly discloses FDA complete response letter for submission of donanemab - The company states: "Eli Lilly announced the FDA has issued a complete response letter for the accelerated approval submission of donanemab for the treatment of early symptomatic Alzheimer's disease due to the limited number of patients with at least 12 months of drug exposure data provided in the submission. No other deficiencies in the application were noted. The confirmatory Phase 3 TRAILBLAZER-ALZ 2 trial remains ongoing, with topline data read-out expected in Q2 2023, and will form the basis of donanemab's application for traditional approval shortly thereafter. Lilly will continue to work with the FDA to evaluate the fastest pathway to make this potential treatment option widely available to patients. In the complete response letter to the accelerated approval application, the FDA specifically requested that Lilly provide data from at least 100 patients who received a minimum of 12 months of continued treatment on donanemab. Donanemab's specificity to target deposited amyloid plaque informed the unique clinical trial design of TRAILBLAZER-ALZ, which allowed patients to complete their course of treatment when they reached a predefined level of amyloid plaque clearance. While the trial included more than 100 patients treated with donanemab, due to the speed of plaque reduction, many patients were able to stop dosing as early as 6 months of treatment, resulting in fewer than 100 patients receiving 12 months of donanemab. The FDA indicated that the data to meet the exposure expectation would likely need to include the unblinded controlled safety data from TRAILBLAZER-ALZ 2 upon completion. The safety profile of donanemab was initially reported from the TRAILBLAZER-ALZ trial in the New England Journal of Medicine. The safety profile of donanemab has remained consistent since our accelerated approval submission."

17:54 EST DiamondHead Holdings chairman buys $2.52M in common stock - In a regulatory filing, DiamondHead Holdings disclosed that its chairman David Hamamoto bought 250K shares of common stock on January 17th in a total transaction size of $2.52M.

17:32 EST BeiGene announces FDA approval of Brukinsa for CLL - BeiGene announced that the FDA has approved its Bruton's tyrosine kinase inhibitor, BTKi, Brukinsa for the treatment of adult patients with chronic lymphocytic leukemia, CLL, or small lymphocytic lymphoma, SLL. The U.S. approval is based on two global Phase 3 clinical trials demonstrating superior efficacy and a favorable safety profile for Brukinsa in CLL.

17:04 EST Redfin: Median U.S. home-sale price increased 0.9% for four weeks ending Jan. 15 - The median U.S. home-sale price increased 0.9% from a year earlier to $350,250 during the four weeks ending January 15, the biggest increase in a month, according to a new report from Redfin (RDFN). Prices remain elevated because buyer activity has started to pick up as mortgage rates decline due to slowing inflation. Average mortgage rates dropped to 6.15% during the week ending January 19, their lowest level since September. Pending home sales fell 29% year over year-a significant decline, but the first sub-30% drop in three months. Mortgage-purchase applications rose 25% from the week before during the week ending January 13, a jump that's likely to lead to more pending sales in the coming months. As demand inches back, some homeowners are less reluctant to sell. New listings of homes for sale fell 20% year over year during the four weeks ending January 15-but that's the smallest decline in two months...Home-sale prices fell year over year in 18 of the 50 most populous U.S. metros during the four weeks ending January 15. By comparison, 20 metros saw a price decline during the prior four-week period and 11 metros saw price declines a month earlier. Other listed companies that may be impacted include Zillow (Z), RE/MAX Holdings (RMAX).

17:01 EST Levi Strauss appoints Jason Gowans Chief Digital Officer - Levi Strauss & Co. announced that Jason Gowans has been named senior VP and Chief Digital Officer for LS&Co., effective February 6. In this new role within the company, Gowans will be focused on bringing together LS&Co.'s engineering, data, AI and digital product management to spearhead digital efforts both for ecommerce and the digital go-to-market. He will report to Michelle Gass, president, LS&Co., and will sit on the executive leadership team. Gowans joins the company from Nordstrom, where he spent the past 10 years in a variety of marketing, data science and digital roles, serving most recently as senior vice president of Digital Commerce, leading the growth of Nordstrom's digital business on Nordstrom.com and NordstromRack.com.

16:56 EST 1st Source reports Q4 net interest margin 3.69% vs. 3.09% y/y - Reports Q4 NII $71.5M vs. $60.1M y/y. Reports Q4 ROE 14.56% vs. 11.97% y/y.

16:53 EST Magnite announces 6% global workforce reduction - In a regulatory filing, Magnite said, "On January 19, the company announced that it would be reducing its global workforce by approximately 6%. The reduction in force is primarily associated with the elimination of duplicative roles resulting from the integration of our CTV platforms and the realization of acquisition operating cost synergies, consistent with our previously announced integration plan following the acquisition of SpotX, Inc. in 2021."

16:41 EST Ralph Lauren CEO sells $2.22M in common stock - In a regulatory filing, Ralph Lauren disclosed that its CEO Patrice Louvet sold 18.5K shares of common stock on January 18th in a total transaction size of $2.22M.

16:39 EST Jabil exec Borges sells 18,525 common shares - In a regulatory filing, Jabil executive VP Steven Borges disclosed the sale of 18,525 common shares of the company on January 17 at a price of $78.52 per share.

16:35 EST Kala Pharmaceuticals falls 10% to $15.90 after equity offering

16:32 EST Astronics spikes over 13% higher after reporting preliminary Q4 revenue - Shares of global aerospace technology firm Astronics are up $1.36 per share or 13.15% to $11.70 after announcing preliminary fourth quarter sales to be in the range of $155M to $160M, exceeding the company's earlier guidance of $140M to $150M. The midpoint of the preliminary range represents a sequential increase in sales of 20% over the third quarter of 2022 and 35% increase over the comparator quarter of 2021. Preliminary bookings in the fourth quarter are expected be in the range of $175M to $180M.

16:31 EST Gulfport Energy names John Reinhart as CEO - Gulfport Energy "named John Reinhart President, CEO and Director, effective January 24, 2023. Tim Cutt, who has served as CEO and Chairman since 2021, will retain his position of Chairman of the Board of Directors. Reinhart joins Gulfport with over two decades of oil and gas industry leadership experience. Most recently, he served as President and Chief Executive Officer of Montage Resources Corporation."

16:29 EST Spirit Airlines to sell 29 A319ceo aircraft for $152M-$201M - In a regulatory 8-K filing, the company states: "Spirit Airlines has entered into an agreement, dated January 13, 2023, to sell 29 unencumbered A319ceo aircraft powered with V2500 engines to Gryphon Trading Company, LLC, an affiliate of Gryphon Aviation Leasing, LLC, for an aggregate price ranging between approximately $152 million and $201 million, depending on price adjustments specified in the Agreement. Deliveries of the aircraft are anticipated to occur beginning in the first quarter 2023 through the end of the third quarter 2024. The company expects to remove 14 and 15 A319ceo aircraft from its operating fleet in 2023 and 2024, respectively. The remaining two A319ceo aircraft in the company's operating fleet, which are leased, are anticipated to be returned to the lessor upon lease expiration in 2025."

16:19 EST Astronics sees Q4 preliminary bookings at $175M-$180M

16:16 EST Ares Capital names Jana Markowicz as Chief Operating Officer - Ares Capita "announced that Jana Markowicz was appointed as its Chief Operating Officer. In this newly created role, Ms. Markowicz will also serve as COO of Ares Management's U.S. Direct Lending strategy where she will collaborate with the U.S. Direct Lending Co-Heads and Investment Committee members in the management of the team and strategy."

16:11 EST South Plains Financial increases quarterly dividend 8% - South Plains Financial announced that its board has declared a quarterly cash dividend of 13c per share of common stock, an 8% increase from the most recent quarterly cash dividend declared in October 2022 . The dividend is payable on February 13 to shareholders of record as of the close of business on January 30.

16:10 EST Netflix completes succession process, Hastings now Executive Chairman - The company said: "To complete our succession process, Reed Hastings has become Executive Chairman, and Greg Peters has stepped up from COO to become Ted Sarandos' co-CEO, and a member of the Netflix board. Reed, Greg, and Ted have been working closely together for 15 years, and this makes formal externally how we have been operating internally." Ted said: "I want to thank Reed for his visionary leadership, mentorship and friendship over the last 20 years. We've all learned so much from his intellectual rigor, honesty and willingness to take big bets - and we look forward to working with him for many more years to come. Since Reed started to delegate management to us, Greg and I have built a strong operating model based on our shared values and like-minded approach to growth. I am so excited to start this new chapter with Greg as co-CEO."

16:10 EST Netflix: Bela Bajaria becomes chief content officer - Bela Bajaria, formerly Head of Global TV, has become Chief Content Officer and Scott Stuber has become Chairman of Netflix Film.

16:08 EST Latham Group CFO Robert Masson to step down - Latham Group announced that Robert Masson will step down as the company's CFO for family reasons, effective March 17. Latham has initiated an external search process for a new CFO. Mark Borseth, who previously served as Latham's CFO from February 2020 to July 2022, will rejoin Latham as a strategic advisor effective February 13. On March 18, Borseth will become the interim CFO until a successor has been named.

16:08 EST Netflix sees resuming share buyback program in 2023

16:06 EST Nordstrom reports holiday sales down 3.5% - Nordstrom announced a net sales decrease of 3.5% for the nine-week holiday period ended December 31, 2022, compared with the nine weeks ended January 1, 2022. For the Nordstrom banner, net sales decreased 1.7%, while net sales at the Nordstrom Rack banner decreased 7.6%. "The holiday season was highly promotional, and sales were softer than pre-pandemic levels. While we continue to see greater resilience in our higher income cohorts, it is clear that consumers are being more selective with their spending given the broader macro environment," said Erik Nordstrom, chief executive officer of Nordstrom, Inc. "Still, our team executed well, and we enter 2023 in a stronger position as we prioritized starting the new fiscal year with clean inventory levels, even if this required more markdowns than planned." The company took additional markdowns in order to finish the year in a healthy and current inventory position. The company expects year-end inventory levels to be down by a double-digit percentage compared with last year, and roughly at 2019 levels. "Having a healthier inventory level and mix positions us well to react quickly to changing consumer demand," said Pete Nordstrom, president and chief brand officer of Nordstrom, Inc. "Given the continued uncertain environment, we remain focused on executing with flexibility and agility, including conservative buy plans and faster inventory turns. We continue to enhance our customer experience with our Closer to You strategy, which links our digital and physical assets. Additionally, we are further optimizing our supply chain to improve the customer experience and expense efficiency, and we expect these initiatives will continue to deliver significant benefits in 2023."

16:06 EST Netflix sees Q1 revenue growth 4%, or 8% on FX neutral basis - Consensus is $8.15B. The company said: "We expect our F/X neutral revenue growth to be driven by a combination of year over year growth in average paid memberships and ARM. This translates into modest positive paid net adds in Q1 '23 (vs. paid net adds of -0.2M in Q1'22). Our expectation of fewer paid net adds in Q1'23 vs. Q4'22 is consistent with normal seasonality and factors in our strong member growth in Q4'22, which likely pulled forward some growth from Q1'23. In addition, we expect to roll out paid sharing more broadly later in Q1'23. We anticipate that this will result in a very different quarterly paid net adds pattern in 2023, with paid net adds likely to be greater in Q2'23 than in Q1'23."

16:05 EST Netflix up 8% in after-hours following Q4 earnings report - Shares of Netflix are up $25.98, or 8%, to $341.76 in after-hours trading after the company reported Q4 results that included better-than-expected streaming paid net additions.

16:04 EST Netflix sees at least $3B of free cash flow in 2023

16:04 EST Texas Instruments names Haviv Ilan as next CEO, effective April 1 - Texas Instruments said that its board of directors has selected Haviv Ilan to become the company's next president and CEO, effective April 1. Ilan, a 24-year veteran of TI, succeeds current CEO and president, Rich Templeton, who will transition out of these roles over the next two months but will remain the company's chairman. The transition is a well-planned succession that follows Ilan's promotion to senior vice president in 2014, executive vice president and chief operating officer in 2020 and election to the board of directors in 2021.

16:03 EST Netflix completes succession process, Hastings now Executive Chairman

16:01 EST Netflix: Reed Hastings becomes executive chairman

15:09 EST CS Disco to reduce workforce by 9% - In a regulatory filing earlier, CS Disco disclosed that on January 19, the company committed to a plan to reduce its workforce by approximately 62 employees, representing approximately 9% of the company's current global workforce. "The plan was based on cost-reduction initiatives intended to reduce the company's cost structure and accelerate its path to profitability. The company estimates that it will incur non-recurring charges of approximately $0.9 million to $1.1 million in connection with the plan, consisting of cash expenditures primarily for employee severance and other termination benefits. The company expects that the majority of these charges will be incurred in the first quarter of 2023. The charges that the company expects to incur are subject to a number of assumptions, including local law requirements in various jurisdictions. Actual expenses may differ from such estimates," the filing stated.

14:21 EST Seagen announces FDA accelerated approval of TUKYSA-trastuzumab combo - Seagen announced that the U.S. Food and Drug Administration has granted accelerated approval to TUKYSA in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. TUKYSA is approved under the FDA's Accelerated Approval Program based on tumor response rate and durability of response from the phase 2 MOUNTAINEER clinical trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This is the first FDA-approved treatment in HER2-positive metastatic colorectal cancer. The FDA previously granted Breakthrough Therapy Designation and Priority Review for TUKYSA in this setting. "Historically, patients with HER2-positive metastatic colorectal cancer who have progressed following frontline therapy have had poor outcomes," said John Strickler, M.D., associate professor of medicine, Duke University Medical Center, and lead investigator for the MOUNTAINEER trial. "The FDA approval of a chemotherapy-free combination regimen that specifically targets HER2 is great news for these patients."

13:40 EST KKR says KREST received repurchase requests for 8.1% of fund's NAV in Q1 - In a regulatory filing earlier, KKR stated: Thank you for your support of KKR Real Estate Select Trust Inc., or "KREST," and for entrusting us with your clients' capital. KREST seeks to provide investors with access to the potential benefits of income-oriented real estate equity and credit in a single fund. As market conditions have evolved and continue to evolve, we remain focused on optimizing the Fund's portfolio across high-quality, income-oriented real estate equity and credit exposures to seek to deliver upon our objectives and provide investors with a resilient and attractive yield and total return and a level of downside protection across a wide range of market environments. Amid an uncertain market environment, KREST delivered an 8.32% net total return for 2022 - Class I - while generating an annualized net distribution rate of 5.13% as of December 31, 2022. Within KREST, we are balancing providing access to private real estate, which is an illiquid asset class, with the recognition and understanding that the optionality for a level of regular liquidity is an important feature for KREST shareholders. To facilitate a level of liquidity and as described in the Fund's prospectus and offer to repurchase, KREST has historically conducted, and intends to continue, quarterly tender offers to repurchase up to 5% of net asset value, or "NAV," of the Fund's outstanding Common Stock, with such tender offers being made at the sole discretion of KREST's Board of Directors. KREST's liquidity provisions are designed both to prevent a liquidity mismatch and to maximize long-term shareholder value. For the Fund's Q1 2023 tender offer period ending January 13, 2023, KREST received repurchase requests of $128 million, or 8.1%, of the Fund's aggregate NAV as of December 1, 2022. While this is elevated relative to prior tender offer periods, KREST has continued to benefit from strong fundraising momentum, with $946.5 million of subscriptions in 2022, including $141.7 million during the 4th quarter. This quarter, KREST repurchased Common Stock equating to 5% of NAV, or $79.3 million. Accordingly, redemption requests were fulfilled at a prorated amount equal to 62% of each shareholder's Q1 2023 tender request. Unfulfilled tender requests will not be carried over to the next quarter automatically. Investors will need to resubmit any unsatisfied portion of their Q1 2023 tender request for repurchase in the future. We believe that KREST has a strong liquidity position, with liquid holdings representing 36% of NAV as of December 31, 2022 across assets such as cash, cash-equivalents and liquid securities, as well as committed and unfunded credit facility capacity. We believe that maintaining a robust liquidity position is a critical component of optimal portfolio construction, particularly in more uncertain market environments such as today's. We expect that our robust, multifaceted approach to liquidity should continue to allow KREST to repurchase Common Stock equating to 5% of NAV during quarterly tender offer periods without any negative impact to portfolio construction, such as being required to exit real estate equity or credit positions at suboptimal or inopportune times. We believe KREST is well-positioned for today's market environment as we seek to continue to deliver upon our objectives for your clients." Reference Link

13:18 EST BMO joins Angel City Football Club as founding partner - Angel City Football Club announced that BMO has joined the ACFC family as a Founding Partner. The announcement coincides with BMO announcing it secured the naming rights to Angel City's home stadium now called BMO Stadium. Angel City will kick off its season at BMO Stadium in downtown Los Angeles in late March 2023.

12:00 EST Energy Vault falls -12.7% - Energy Vault is down -12.7%, or -61c to $4.19.

12:00 EST Innovative Industrial Properties falls -15.9% - Innovative Industrial Properties is down -15.9%, or -$17.61 to $93.27.

12:00 EST Direxion Daily Semiconductor Bear 3X Shares rises 9.1% - Direxion Daily Semiconductor Bear 3X Shares is up 9.1%, or $2.60 to $31.31.

11:38 EST Playtika raises bid to buy Rovio Entertainment to EUR 9.05 per share - Playtika announced it submitted a revised proposal to the Board of Directors of Rovio Entertainment Corporation to acquire Rovio for EUR 9.05 per share in cash. "The non-binding proposal, which is not subject to any financing conditions, was submitted to the Rovio Board of Directors on January 19, 2023, and represents an improvement over an initial EUR 8.50 per share proposal submitted November 16, 2022. The proposal is subject to customary conditions, including without limitation satisfactory completion of due diligence and recommendation of the Rovio Board of Directors. At the present time, no agreement has been entered into between Playtika and Rovio and there is no assurance that any transaction will materialize or eventually be completed," the company stated. "We firmly believe the combination of Rovio's renowned IP and scale of its user base, together with our best-in-class monetization and game operations capabilities, will create tremendous value for our shareholders," added Playtika CEO Robert Antokol.

11:03 EST Alta Fox sends letter to Daktronics' directors urging leadership transition - Alta Fox Capital Management, which owns about 4% of Daktronics' outstanding common shares, sent a letter to Daktronics' independent directors, urging them to immediately announce an orderly leadership transition. The letter says in part: "The purpose of this letter is to inform you that Alta Fox will no longer wait for a substantive response to the month-old proposal we made pertaining to governance enhancements and a financing solution. Your silence leads us to believe you are either unable or unwilling to make the difficult - albeit necessary - decision to move on from both Chairman and CEO Reece Kurtenbach and CFO Sheila Anderson. As such, we intend to make the market aware of the following: Over the past month, despite the Company's dire situation, we have not received a single mark-up to the term sheet from the Company. Meanwhile, the Company has hired a chorus of advisors while its cash balance dwindles... Daktronics makes great products and has incredible talent throughout the organization. We saw firsthand the many South Dakota employees who have worked hard to be at the cutting edge of their industry. It is very unfortunate that many of these employees have seen their retirement investments in Daktronics decline over a 20-year period due to seemingly incompetent leadership. We have run out of patience. Short of you informing us that Mr. Kurtenbach and Ms. Anderson will be transitioning out of their current executive roles, we intend to take our case to shareholders over the coming weeks and months. It is regrettable that you have forced us to take this step and, in turn, make other market participants aware of the Kurtenbach-driven damage caused at Daktronics. We simply hope the damage is not irreversible."

10:07 EST Astellas Pharma to present findings from Phase 3 SPOTLIGHT trial - Astellas Pharma will present detailed results from the Phase 3 SPOTLIGHT trial evaluating first-line treatment with zolbetuximab, an investigational first-in-class Claudin 18.2 targeted monoclonal antibody, plus mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.In the study, investigational treatment zolbetuximab plus mFOLFOX6 demonstrated statistically significant improvements in progression-free survival and overall survival compared to placebo plus mFOLFOX6. Specifically, zolbetuximab plus mFOLFOX6 reduced the risk of progression or death by 24.9% compared to placebo plus mFOLFOX6, meeting SPOTLIGHT's primary endpoint. Median PFS was 10.61 months in the treatment arm and 8.67 months in the placebo arm. The study also showed that zolbetuximab plus mFOLFOX6 significantly prolonged OS, reducing the risk of death by 25.0%. Median OS was 18.23 months and 15.54 months for the treatment arm and placebo arm, respectively. The incidence of serious treatment-emergent adverse events was similar between both arms and consistent with previous studies. The most frequent TEAEs in the SPOTLIGHT study were nausea, vomiting and decreased appetite.

10:00 EST Gorilla Technology Group Inc trading resumes

10:00 EST Innovative Industrial Properties falls -13.3% - Innovative Industrial Properties is down -13.3%, or -$14.77 to $96.11.

10:00 EST Comerica rises 7.9% - Comerica is up 7.9%, or $5.21 to $71.16.

10:00 EST New Oriental Education rises 9.9% - New Oriental Education is up 9.9%, or $4.02 to $44.79.

09:52 EST The Hanover estimates Q4 catastrophe losses of $190M before taxes - The Hanover Insurance Group announced a preliminary estimate for fourth quarter catastrophe losses of approximately $190M, before taxes, or 13.9 points of net earned premiums. The estimate is approximately $137M above the company's pre-tax fourth quarter catastrophe assumption, driven by the effects of Winter Storm Elliott, which accounted for approximately $165M, before taxes, of overall catastrophe losses in the quarter and primarily impacted the company's core commercial business. "We have a robust track record of successful catastrophe exposure management, risk modeling and portfolio diversification initiatives, as demonstrated by our relatively low catastrophe losses from hurricanes and other traditional perils in the recent years. And, we are confident in our ability to address winter weather and water-related events through pricing, risk management and other innovative tools effectively," said CEO John Roche. "Looking beyond catastrophes, we successfully advanced our action plans towards recapturing target margins in property lines, achieving double digit renewal price increases in all three business segments in the fourth quarter." The Hanover expects its fourth quarter combined ratio, excluding catastrophes, to be 94.1%. As a result, the company expects its full year combined ratio, excluding catastrophes, to be 92.1%, consistent with the outlook range of 92.0% to 92.5% provided on its third quarter earnings call. Taking this and other currently available information into account, The Hanover expects to report an after-tax net loss per share of $0.33 and operating loss per share of $1.05 for the fourth quarter.

09:50 EST Gorilla Technology Group Inc trading halted, volatility trading pause

09:47 EST Unifi falls -12.7% - Unifi is down -12.7%, or -$1.13 to $7.77.

09:47 EST Compass Diversified rises 4.2% - Compass Diversified is up 4.2%, or 86c to $21.28.

09:47 EST Chegg rises 4.4% - Chegg is up 4.4%, or 89c to $21.27.

09:46 EST Graham Holdings raises quarterly dividend to $1.65 from $1.58 per share - Payable on February 16 to shareholders of record on February 2.

09:43 EST GE Aerospace, Cargolux enter long term GE9X, GEnx agreements - GE Aerospace & Cargolux announce that they have entered into a long-term support agreement for the GE9X powering Cargolux's new fleet of Boeing 777-8 freighters. The agreement includes a multi-year GE TrueChoice service agreement as well as the order of two spare engines. A TrueChoice services extension has also been agreed for Cargolux's fleet of Boeing 747-8F fleet powered by GEnx-2B engines. "We are proud that Cargolux continues to choose GE Aerospace to power its modern, highly-efficient cargo fleet," said Russell Stokes, President and CEO, Commercial Engines and Services for GE. "Our focus remains to provide Cargolux with outstanding engines like the GE9X in terms of technology and performance, as well as world-class support."

09:40 EST Advaxis, Ayala Pharmaceuticals complete merger - Advaxis (ADXS) announced the completion of a previously announced merger with Ayala Pharmaceuticals (AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the name Ayala Pharmaceuticals. The merged company will be focused primarily on the development and commercialization of Ayala's lead program AL102 for the treatment of desmoid tumors. As previously disclosed, the company is seeking to uplist to Nasdaq in the near future, but there is no guarantee that this effort will be successful. Kenneth Berlin, President and CEO of Advaxis, will be President, CEO and a Director of the company; Andres Gutierrez, M.D., Ph.D., will be the CMO; and Igor Gitelman will be the Interim CFO. The board of directors consists of David Sidransky, M.D., as chairman, Roni Appel, Samir Khleif, M.D., Vered Bisker-Leib, M.D., Murray A. Goldberg, Robert Spiegel, M.D., and Ken Berlin.

09:31 EST Wildpack Beverage reports December confirmed customer orders totaling $5.68M - Wildpack Beverage announce its December 2022 sales and production highlights, and a significant quality assurance achievement for the Company. With confirmed customer orders totaling $5,683,527 and a record-breaking 224 confirmed sales orders, the Company had a very strong finish to the year. In addition to these impressive achievements, Wildpack also saw a record number of new customer conversions, with 53 new customers added to the Company's growing diversified list. The Company also set a new record in total throughput, with 23,956,748 cans produced. This included decoration throughput of 2,987,095 cans, filling throughput of 2,123,339 cans, and printed sleeve throughput of 3,151,473 sleeves. The Company also set a new record in brokering throughput, with 15,694,841 can and can equivalents brokered. In terms of plant utilization, the Company had a strong performance notwithstanding December is typically a slower month for the beverage co-packing industry, with a utilization rate of 25%. The Company is also honored to announce that its Baltimore, Maryland plant has received the coveted Safe Quality Food designation, demonstrating the Company's on-going commitment to producing safe and high-quality products for its customers.

09:29 EST Planet 13 Holdings announces fourth Florida dispensary in Port Orange - Planet 13 Holdings announced the fourth location of its planned Florida dispensary network located in the city of Port Orange on the 'Fun Coast.' Port Orange is in the Deltona-Daytona Beach-Ormond Beach metropolitan area, a popular tourist destination with a growing population of over 600,000.

09:28 EST Avenir Wellness to launch Wall Street-focused informational series - Avenir Wellness Solutions is launching an informational series to inform the Wall Street community about its unique dual revenue model involving breakthrough consumer wellness products and intellectual property monetization. Avenir has retained producer New to The Street to create sponsored television content featuring Avenir's leadership that will be nationally and internationally syndicated on major television networks.

09:26 EST Golar LNG unwinds majority of swap arrangements for Dutch TTF exposure - Golar LNG announces hat it has unwound the majority of its swap arrangements for its Dutch Title Transfer Facility inked production on the FLNG Hilli: March-December 2023, securing approximately $76 million of Distributable adj. EBITDA: 100% of TTF linked production unwound at $21.80/MMBtu leading to a net gain of $28.2/MMBtu, equivalent to Distributable Adjusted EBITDA of $76 million to be received in ten equal monthly installments through the period March-December 2023. Full year 2024, securing approximately $49 million of Distributable adj. EBITDA: 50% of TTF linked production unwound at $20.55/MMBtu leading to a net gain of $30.65/MMBtu, equivalent to Distributable Adjusted EBITDA of $49 million to be received in twelve equal monthly installments through 2024. Golar's only remaining TTF hedges are January and February 2023, with an estimated Distributable Adjusted EBITDA of approximately $25 million, which includes Golar's share of TTF invoices for the same period. The total secured value from the TTF hedges entered into in Q3 2022 amounts to approximately $140 million, or approximately $1.3 in cash flow per share. Golar maintains exposure to its TTF linked tariff for the FLNG Hilli, where 2023 earnings sensitivity is $2.7 million for every $1/MMBtu change in TTF, $3.2 million for every $1/MMBtu change in TTF for 2024-2025 and $1.7 million for every $1/MMBtu change in TTF from Jan-July 2026. At the current forward curve, this is equivalent to $47 million of Distributable Adjusted EBITDA for 2023 and $56 million for 2024. Golar's share of Hilli Distributable Adjusted EBITDA is expected to be approximately: 2023: $282m. This includes locked in TTF curves of $101 million, TTF linked earnings of $47 million based on 2023 TTF forward price of $20.8/MMBtu, and current Brent linked earnings of $67 million based on 2023 forward price at $84/bbl and base tariff of $67 million.2024: $225m. This includes locked in TTF curves of $49 million, TTF linked earnings of $56 million based on 2024 TTF forward price of $20.9/MMBtu, and current Brent linked earnings of $53 million based on 2024 forward price at $79/bbl and base tariff of $67 million. Golar's share of expected annual debt service for Hilli's contractual debt is approximately $50 million.

09:23 EST Ondas receives network controller order from Siemens Mobility - Ondas Holdings (ONDS) announced that Ondas Networks has received a development order from Siemens Mobility (SIEGY) on behalf of MxV Rail, a wholly owned subsidiary of the Association of American Railroads. The order is for the design and development of a software-based "Network Controller." The Network Controller enables the Class 1 Railroads to optimize the use of their FCC-designated licensed frequencies within and across multiple frequencies, networks, railroads, and applications.

09:22 EST Eagle Bulk Shipping appoints Kate Blankenship to board - Eagle Bulk Shipping announced that it has appointed A. Kate Blankenship to its Board of Directors, effective January 18. Blankenship is a member of the Institute of Chartered Accountants in England and Wales (ICAEW). In addition to having served in key senior management positions, Ms. Blankenship has served as a director at a number of U.S.-listed companies within the shipping and energy industries, including; Frontline, Golden Ocean, Golar LNG, International Seaways, and Seadrill.

09:20 EST Mondelez releases fourth annual State of Snacking report - Mondelez International today announced the launch of the fourth annual State of Snacking(TM) report, a global consumer trends study examining annual insights on how consumers make snacking decisions. This year's report explores how current economic challenges are affecting consumer snacking choices around the world - with a majority of respondents continuing to prioritize snacking, despite rising costs and economic challenges. Developed in partnership with The Harris Poll, the report tracks snacking attitudes and behaviors among thousands of consumers surveyed across 12 countries for a fourth consecutive year. These findings illustrate the expanded role of snacking- as snacking increasingly replaces traditional meals in consumers' lives. Key findings include that consumers around the world are snacking:Daily - Snacking is a staple - 71 percent of consumers snack at least twice a day. Mindfully - 78 percent of consumers report they take time to savor indulgent snacks with 61 percent saying they take time to portion out snacks before eating them. Frequently - Consumers are increasingly replacing meals with snacks, with 55 percent reporting a higher likelihood to eat a snack across all three standard mealtimes. Sustainably - Reducing waste is a top priority, with seven in 10 consumers saying they prioritize snacks that have less packaging and 72 percent saying they typically recycle it.

09:18 EST Dorian LPG says positioned for market growth, green shipping challenges - Capital Link hosted a presentation by the senior management of Dorian LPG on Thursday, January 12, 2023. During the 45-minute session, John Lycouris, Dorian LPG USA CEO, and Ted Young, Dorian LPG CFO, provided an image of the growing LPG market and VLGC sector as part of Capital Link's Company Presentation Series. LPG has risen in prominence as an alternative to gasoline, coal, and oil due to its low cost, abundant supply, and portability. While it is a fossil fuel, LPG is also cleaner than many other energy sources, as it produces less air pollution and carbon emissions.The war in Ukraine has greatly impacted the price of LNG, particularly in the Far East, where it has increased significantly. As Russia did not export a significant amount of LPG before the war, and what it did export was transported largely by rail and mid-size vessels (MGCs), the war and resulting sanctions did not impact the VLGC sector much directly. It did, however, create additional LPG exports from other oil and gas producing countries, thereby bolstering the VLGC sector ton-miles. "Global demand for LPG is about 330 million metric tons, about one third of that is traded over the water" on VLGCs, Ted Young, CFO, stated. North America and the Middle East are the largest production centers for LPG, while the major end-user markets are mainly located in the Far East. The USA has become the biggest seaborne exporter of LPG, with the Middle East following close behind. In 2022, 45% of global LPG exports came from the US, and 36% from the Middle East. The EIA forecasts that production of LPG will increase by 5 to 6% in the US in the next two years, while LPG exports are expected to increase by 16% in 2023, and by 8% percent in 2024. Ted Young noted that the company has "made a significant investment in scrubbers," as 13 of its vessels are scrubber-fitted, a move which "has paid big dividends." Without scrubbers, the ships would have to operate on highly expensive low-sulphur fuel oil in order to follow the 2020 IMO regulations on sulphur emissions pollution. However, ships fitted with scrubbers can operate on lower-cost, standard fuel oil, since the scrubbers remove the offending pollutant...Unlike many other shipping sectors, the VLGC orderbook is quite large, with 70 ships on order from now until 2025, 45 of which are expected to be delivered this year alone. While such a large orderbook could be a cause for concern, there are a number of factors at play that may mitigate some of the market risk. "No one likes to have this many ships come into his market...but, per the EIA, the US expects pretty explosive export growth this year," Ted Young stated. He also noted that 60 vessels on the water-18% of the global VLGC fleet-are due for drydocking and special surveys in 2023, meaning that they will be "out of commission" for four to six weeks. Additionally, a significant portion of VLGCs on the water are ageing out, with 17% of the global fleet aged over 20 years, meaning that a significant number of vessels will have to be significantly renovated or scrapped in order to remain economically viable, particularly in terms of IMO regulations. While only one ship was scrapped in 2022, there are 58 ships currently on the water that are candidates for scrapping.

09:16 EST Crypto Company expands sales team - The Crypto Company initiates an expansion of its sales team. Through its wholly owned subsidiary, Blockchain Training Alliance, the company plans to expand its sales team to more than twenty in 2023, all of which will include new sales, sales management and sales operations positions. In December, The Crypto Company contracted with and trained six independent sales professionals located in various states around the U.S.

09:15 EST Koil Energy to provide subsa equipment for Shenandoah development - Koil Energy Solutions announced the receipt of an order to provide subsea distribution equipment for the Shenandoah project, a 17,500 psi development in the US Gulf of Mexico. The multi-million-dollar project is for the provision of 70+ Multi Quick Connect plates, which are critical pieces of subsea infrastructure used to enable the transfer of different fluids between subsea systems. The equipment will be qualified for 20,000 psi applications. The project is expected to be substantially complete by the end of 2023.

09:14 EST Rumble releases TV app for subscription platform - Rumble announced the next-generation TV app of its subscription-based community platform, Locals. The LocalsTV app is now available through AppleTV and Roku and remains available through GoogleTV and FireTV.

09:13 EST Kopin provides restructuring update - Kopin Corporation provided an update on its restructuring activities. "On January 5, 2023, we announced a restructuring, which included the partial spinout of our OLED development unit and a reduction in force," said Michael Murray, Kopin's Chief Executive Officer. "This week, we informed our employees that to accelerate application understanding, drive efficiencies and increase focus, we have reorganized the Company. We are confident these changes, along with the steps taken in the prior quarter, will lead to improved functional expertise, focus, and leadership. One of the key changes is separating business and program capture from program management. This will ensure focus on filling our pipeline with opportunities that align with our strategic plan, whilst we deliver to our customers 'on time and in full,' which is critical for profitability. To this end, we have been performing program reviews with our customers, and in some cases slowing deliveries to ensure we are delivering the highest quality products. In addition, in select situations, we are negotiating potential exits from non-profitable endeavors, if they cannot be rectified. These actions had some impact on revenue in the fourth quarter of fiscal 2022 and we expect revenue for the fourth quarter will be approximately $11.0 to 11.5 million. In addition, we anticipate these actions will lead to less revenue in the first quarter of fiscal 2023 and for the remainder of fiscal year 2023. Although these decisions are difficult and impactful, they are critical to align with our renewed focus on quality, on time delivery and operational excellence while driving towards our goals of long term, sustainable and profitable growth," concluded Mr. Murray.

09:11 EST MasterCard, Citizens Financial announces exclusive payments partnership - Mastercard (MA) and Citizens (CFG) announced an expanded partnership, making Mastercard the exclusive payments network across Citizens' credit, debit and commercial portfolios, as well as services provider in the U.S. With shared values and vision, Citizens and Mastercard are united in the goal to provide access, inclusion and innovation to the communities they serve. "Mastercard is thrilled to enhance our partnership with Citizens to become their exclusive payments provider across all product portfolios," said Linda Kirkpatrick, president, North America at Mastercard. "We are proud to work with a brand that champions financial empowerment, and we look forward to bringing new products, services and capabilities to complement the strong value proposition Citizens provides to consumers and businesses."

09:10 EST CleanSpark breaks ground on 50 mw bitcoin mining expansion - CleanSpark announced that it has started construction on the second phase of one of its newest sites in Washington, Georgia. The Company acquired this campus in August of 2022 as part of its recent bear-market growth campaign. Upon completion, the new phase, which is expected to employ only the newest generation of bitcoin mining machines, will add up to 2.2 exahashes per second of computing power to the Company's mining capacity. The mining machine fleet at the new phase will consist of Antminer S19j Pro and Antminer S19 XP models, the newest and most power-efficient models of bitcoin mining machines available today. Depending on the final number of each model in the mix, the total computing power that will be added to CleanSpark's bitcoin mining capacity will range from 1.6 EH/s to 2.2 EH/s - a 25% to 34% increase from its current hashrate of 6.5 EH/s.

09:10 EST CW Network, LIV Golf enter multi-year agreement - The CW Network, owned by Nexstar Media, and LIV Golf announced they have entered into LIV's first-ever U.S. broadcast television and streaming agreement. The CW is set to become LIV's exclusive broadcast partner with a multi-year agreement beginning with the 2023 LIV Golf League season. As LIV's exclusive broadcast home in the U.S., The CW Network will air 14 global LIV Golf League live events in 2023 and will stream the events live on The CW App. Financial terms of the agreement were not disclosed. Dennis Miller, President, The CW Network, said, "For The CW, our partnership with LIV Golf marks a significant milestone in our goal to re-engineer the network with quality, diversified programming for our viewers, advertisers and CW affiliates. This also marks the first time in The CW's 17-year history that the network is the exclusive broadcast home for live mainstream sports."

09:09 EST Senmiao Technology reports December operating metrics for ride-hailing platform - Senmiao Technology announced operating metrics for its proprietary online ride-hailing platform for December 2022. In December 2022, Senmiao and its affiliates recorded approximately 0.7 million total completed orders, compared to approximately 0.8 million total orders completed in November 2022. The decrease was the result of a severe outbreak of COVID-19 cases in Senmiao's key city of Chengdu in mid-December, after the lifting of domestic restrictions as China stopped executing its zero-COVID policy. Since the launch of Senmiao's online ride-hailing platform in October 2020, nearly 20.8 million rides have been completed using its own platform. The number of drivers completing rides via all the platforms - known as Active Drivers - in December 2022 was 6,682, down approximately 4.8% from 7,019 in November 2022.

09:08 EST Panbela: EMA adopts decision for SBP-101 as orphan medicinal product - Panbela Therapeutics announced that the European Medicines Agency EMA Committee for Orphan Medicinal Products has issued the Adoption of Commission Implementing Decision relating to the designation of ivospemin, SBP-101 as an orphan medicinal product in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, PDA . The Commission adopted the decision on January 13, 2023 and it will be published for information in all official languages of the EU in the Community Register of Orphan Medicinal Products . Previously, the U.S. Food and Drug Administration granted orphan drug designation to SBP-101. "We are pleased to receive notice that the European Commission has adopted the positive decision for orphan drug designation from EMA's Committee for Orphan Medicinal Products," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "The designation of orphan drug status within the EU is an important achievement as we continue to advance the global ASPIRE trial with the potential that this may be an option for patients with first line metastatic pancreatic cancer in the future."

09:07 EST Allegiant Travel reports FY22 total system passengers up 23.2% y-o-y - Allegiant Travel reported preliminary passenger traffic results for FY22. Total system passengers were up 23.2%, ASMs were up 5.3%, departures were down 0.9%, vs. FY 2021. Scheduled service passengers were up 23.1%, ASMs were up 5.2%, departures were down 0.8%, ASMs were down 5.2% vs. FY 2021.

09:06 EST Openmarkets signs business combination agreement with Broad Capital Acquisition - Openmarkets Group and Broad Capital Acquisition Corp. entered into a definitive Agreement and Plan of Merger and Business Combination Agreement that upon closing will provide the opportunity for OMG to become a publicly traded company. The transaction is expected to be completed in the second quarter of 2023, subject to regulatory approvals and other customary closing conditions. As of the closing, the combined entity, OMGL Holdings Ltd, an Australian public company, is expected to be listed on the Nasdaq Capital Market. The transaction reflects an estimated proforma enterprise value for OMG of US$90 million, with another potential US$20 million in earnout over 2 years, and marks an important step in OMG's overall growth and capital management strategy. Following a period of strategic realignment, the company's capital-raising initiatives are focused on driving the company's renewed growth agenda, exploring strategic M&A to drive revenue synergies through the expansion of product and market portfolios, and continuing to invest in the development of innovative technologies to connect fintech clients and investment professionals to domestic and international markets. As part of the transaction, OMG will retain its experienced management team, led by CEO Dan Jowett. The board of directors of the combined company will consist of seven directors, of whom two individuals will be designated by BRAC and of whom five individuals will be designated by OMG. Upon the closing of the transactions contemplated by the Merger Agreement, BRAC will be merged with a subsidiary of OMGL called OMGH Merger Sub Corp., a Delaware company and wholly owned subsidiary of OMGL with BRAC surviving the merger as a subsidiary of OMGL, after which BRAC will be liquidated and distribute its assets to OMGL. OMG's shareholders will then contribute their shares in OMG to OMGL in exchange for newly-issued shares in OMGL, resulting in OMG becoming a direct wholly owned subsidiary of OMGL. Pursuant to the terms of the Merger Agreement, the consideration to be paid in newly issued ordinary shares of OMGL at a deemed price of $10.00 per share at the closing of the Business Combination to existing shareholders of OMG is to be based upon a calculation of a US$90 million base enterprise value, further adjusted for any cash and outstanding debt of OMG and other customary closing adjustments, with another US$20 million deposited with an independent escrow agent to support an agreed earnout structure. The Consideration excludes certain transaction costs, the net cash and debt of OMG as at closing and an estimate of the working capital adjustment described below. Out of the closing Consideration, shares having a deemed value of approximately US$16 million will be deposited with an independent escrow agent to support certain indemnifications given by OMG under the Transaction. The Business Combination has been approved by the boards of directors of each of BRAC and OMG and by the shareholders of OMG. The Business Combination will require the approval of the shareholders of BRAC and is subject to other customary closing conditions, including a definitive proxy statement on Schedule 14A of BRAC being filed with and cleared by the U.S. Securities and Exchange Commission. The transaction is expected to close in the second quarter of 2023.

09:02 EST Energy Services of America announces special dividend of 5c per share - Payable on February 15 to shareholders of record as of January 31.

09:00 EST Atlis Motor Vehicles to presents strategies on building charging infrastructure - Atlis Motor Vehicles announced that Victor Atlasman, Director of Engineering, Charging Ecosystems and Energy Storage Solutions, will present Strategies to Build and Expand Charging Infrastructure at EV Charging Infrastructure Conference and Exhibition 2023 in Long Beach, CA on February 20, 2023. With more than a decade of experience developing and maintaining EV charging systems and having worked on the first deployment of EVSE's in the US, Mr. Atlasman will share how Atlis Motor Vehicles intends to develop and deploy Megawatt Charging Systems. In addition to addressing the challenges facing today's EVSE manufacturers, he will dive into the impact energy storage systems can have on local communities.

08:58 EST Zentek enters distribution agreement with Southmedic - Zentek has signed a Distribution Agreement with Southmedic for the distribution of Zentek's patented ZenGUARD surgical masks. Under the agreement, Southmedic will be the distributor of ZenGUARD-enhanced surgical masks to the Canadian hospital, general practitioner, private surgery, long-term care and nursing home markets.

08:56 EST Sonnet BioTherapeutics announces data in Phase 1 trial of SON-1010 - Sonnet BioTherapeutics Holdings announced that pharmacokinetic profile simulation of SON-1010 dosing has been completed in its randomized, placebo-controlled Phase 1 clinical trial in healthy volunteers. Historically, the therapeutic application of cytokines has been limited by relatively short half-lives and off-target toxicities that are typically associated with peak plasma levels. SON-1010 is a proprietary version of recombinant human interleukin-12, configured using Sonnet's Fully Human Albumin Binding technology, which has been shown to extend PK and to reduce peak drug levels for improving pharmacodynamic toxicity. The FHAB technology was designed to promote targeting to the tumor microenvironment, particularly when levels of Secreted Protein Acidic and Rich in Cysteine are elevated in the TME. Study SB102 is a single-ascending dose trial in healthy volunteers that was initiated in July, 2022 to address the safety, PK, and PD of SON-1010 in subjects without interference from prior chemotherapy. The Safety Review Committee has found no significant safety concerns to date and has approved advancing to each higher dose level. Typical dose-related increases were seen with SON-1010 using a validated electrochemi luminescence assay after subcutaneous administration. Drug levels peaked at about 11 hours with a geometric mean maximum concentration of 29, 68, and 125 pg/mL for the 50, 100, and 150 ng/kg dose groups, respectively. The mean elimination half-life after a 150 ng/kg dose of SON-1010 was 112 hours, compared to 12 hours for rhIL-12. Observed increases in IFNg were most pronounced and were dose-related, controlled, and prolonged. SON-1010 induced IFNg in all active-drug subjects, which peaked at 24 to 48 hours then returned to baseline after 2 weeks. The IFNg geomean Cmax was 398, 384, and 666 pg/mL after 50, 100, or 150 ng/kg of SON-1010, respectively, while the AUC over 48 hours was 6050, 10200, and 14600 h*pg/mL. Linear regression was used to predict the IFNg Cmax at higher doses, which remain well within the range of safety. Low amounts of IL-10 were induced in a dose-dependent manner, which could also be due to the increase in IFNg. There were small transient increases in IL-6, IL-8, and TNFalpha after dosing but no consistent pattern was seen with IL-1beta, IL-2, or IL-4 and there was no evidence of cytokine release syndrome . Safety was consistent with what has been reported previously; adverse events have generally been mild/moderate, transient in nature, and have all been tolerable.

08:54 EST NeuroSense reports final results from Alzheimer's combination platform study - NeuroSense announced final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease. Preliminary results from the study showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. Based on these preliminary results, NeuroSense expanded the study with a larger healthy control group to further validate the results. TDP-43 has been found in up to 57% of AD cases. NeuroSense's platform combination therapy technology has already shown a statistically significant reduction of TDP-43 in a Phase 2a clinical trial biomarker study in amyotrophic lateral sclerosis, and is now being evaluated in a Phase 2b ALS double-blind clinical trial. NeuroSense believes these most recent biomarker results show the importance of TDP-43 pathology in AD and suggest the potential efficacy of NeuroSense's platform technology in Alzheimer's disease. NeuroSense plans to commence a Phase 2 double-blind proof-of-concept study in Alzheimer's disease in the first half of 2023.

08:53 EST Proxy advisory firms recommend O2Micro holders vote for going private deal - O2Micro International Limited announced that both Institutional Shareholder Services and Glass Lewis have recommended that O2Micro shareholders vote for the proposed going private transaction for $5.0 per American Depository Share or U 0.1 per ordinary share in cash, as contemplated in the Company's previously announced Agreement and Plan of Merger dated September 30 among the Company, FNOF Precious Honour Limited and Rim Peak Technology Limited, a wholly owned subsidiary of Parent, pursuant to which Merger Sub will merge with and into the Company, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of Parent.

08:51 EST Salarius Pharmaceuticals to present SP-3164 preclinical data - Salarius Pharmaceuticals announces that Aundrietta Duncan, Ph.D., director of non-clinical development, will present SP-3164 preclinical data and discuss program progress at the inaugural Molecular Glue Drug Development Summit being held on January 24-26, 2023 in Boston. Dr. Duncan's presentation, titled "Development of the Cereblon-Binding Molecular Glue, SP-3164," will take place during the afternoon session on January 26. Daniela Santiesteban, Ph.D., Salarius' director of targeted protein degradation, will serve as chair for this afternoon session, which is titled "Elevating the Biological Relevance & Therapeutic Value of Molecular Glues from Discovery to Clinical Development." Dr. Duncan will present in vivo data demonstrating the activity of SP-3164 therapeutic activity in cancer models and in vitro data demonstrating SP-3164's mechanism of action. She also will discuss the overall progress of SP-3164 development. SP-3164 is an oral, next-generation molecular glue that uses Salarius' deuterium-enabled chiral switching platform to stabilize the preferred-enantiomer of avadomide, an extensively studied clinical compound that has demonstrated encouraging single-agent and combination-therapy clinical efficacy in non-Hodgkin's lymphomas and other hematologic malignancies. Addition of deuterium at the chiral center of the molecule prevents conversion to the unwanted-enantiomer allowing for isolation and development of the preferred-enantiomer into a potential new cancer treatment. As such, SP-3164 is a new chemical entity and has been issued a composition of matter patent. Data presented in December 2022 at the American Society for Hematology Annual Meeting showed compelling SP-3164 activity in lymphoma models and supports SP-3164's potential in NHL for the clinical trial planned to initiate in 2023.

08:49 EST Sellas Life Sciences to host KOL webinar on GPS AML program - SELLAS Life Sciences Group will host a virtual key opinion leader event to discuss the current treatment landscape for patients suffering from acute myeloid leukemia and the potential for galinpepimut-S as a treatment solution. The webinar event will feature Omer Jamy, MD who is principal investigator of the Phase 3 REGAL study at the University of Alabama at Birmingham, one of the highest enrolling REGAL sites. He is currently Assistant Professor of Medicine at UAB in the Division of Hematology and Oncology and Associate Scientist, Experimental Therapeutics at the O'Neal Comprehensive Cancer Center. Dr. Jamy is principal investigator on several clinical trials in addition to REGAL, focusing on AML, chronic myelogenous leukemia, and allogeneic stem cell transplantation. Dr. Jamy completed his internal medicine residency at the University of Tennessee in Memphis followed by fellowship training at UAB in hematology/oncology, bone marrow transplantation and cellular therapy. The SELLAS management team will provide a corporate update on GPS, their lead pipeline candidate, which is currently being evaluated in a Phase 3 registrational clinical trial in AML patients who have achieved complete remission following second-line salvage therapy. GPS targets malignancies and tumors characterized by an overexpression of the WT1 antigen, one of the most widely expressed cancer antigens in multiple malignancies.

08:45 EST Dyadic International sells equity interest in Alphazyme for $1.27M - Dyadic International announced that it received approximately $1.27M in connection with the sale of its equity interest in Alphazyme. Dyadic received its equity as part of the consideration for the grant of a non-exclusive license to certain of Dyadic's technology. Additionally, under that arrangement Dyadic has the right to receive milestone and royalty payments based on sales of C1 expressed products by Alphazyme. Dyadic also has the potential to receive additional payments based on the future sales of Alphazyme's existing products.

08:44 EST Huadi International enters partnership with Huanqiu on seamless pipe supply - Huadi International Group announced that the Company has entered into strategic partnership agreement with China Huanqiu Contracting & Engineering, HUDI has been awarded and nominated as Huanqiu's first-tier supplier of stainless steel seamless pipes and tubes. Pursuant to the Agreement, HUDI will supply stainless steel seamless pipes and tubes to Huanqiu and its affiliated subsidiaries as part of Huanqiu's procurement process for contracted construction projects.

08:42 EST Procter & Gamble says Q2 growth broad based across business units - Says China market continued to be impacted by Covid lockdowns. Expects slow recovery, modest improvement in the near term. Says had gross margin pressure from commodities and FX. Expects more volatility in costs, currencies in 2H23. Says FX a "significant" y/y headwind. Sees $6B-$8B of share repurchases in FY23. Comments taken from Q2 earnings conference call.

08:41 EST Longeveron announces publication of final data from ELPIS I trial - Longeveron announced the publication of the full results from the Company's ELPIS I trial of Lomecel-BTM for hypoplastic left heart syndrome in the European Heart Journal Open. In the uncontrolled open-label Phase 1b study entitled "Intramyocardial cell-based therapy with Lomecel-B during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: The ELPIS phase I trial," patients underwent the Glenn Procedure at approximately 4-5 months old, and received intracardiac injections of Lomecel-BTM. The ELPIS I study was conducted by a consortium of leading pediatric cardiac surgeons led by Sunjay Kaushal, M.D., Ph.D., currently Division Head of Cardiovascular-Thoracic Surgery at Lurie Children's and principal investigator of the ELPIS I study. The findings of the study included: None of the children experienced the prespecified safety endpoint over one year of follow-up. The procedure was generally well-tolerated in all ten study participants. The babies maintained their weight-for-age z-score after the surgery, and all were alive and transplant-free one year following the procedure. Several indices of right ventricular function, notably the tricuspid regurgitation fraction, showed suggestions of either improvement or prevention of deterioration over one-year following the surgery. In a sub-study of 6 babies, a blood test showed evidence of the persistence and activity of Lomecel-BTM one week after injection. Longeveron is currently enrolling patients in the ELPIS II trial, a 38-patient, randomized, blinded, controlled Phase 2a clinical trial intended to evaluate the safety and efficacy of intramyocardial injection of Lomecel-BTM in infants with HLHS who are undergoing the Glenn Procedure. This ongoing trial is funded by a grant from the National Heart, Lung, and Blood Institute. Lomecel-BTM for HLHS has received Fast Track, Rare Pediatric Disease, and Orphan Drug Designations from the U.S. Food and Drug Administration.

08:39 EST Streamline Health expands RevID agreement with provider network - Streamline Health Solutions announced an expansion of its existing relationship with a prominent healthcare system that manages 80+ facilities throughout the United States. The health system has further expanded its use of RevID. The Company also announced that it has now exceeded its previously stated goal of $17M of booked SaaS ACV by the end of its fiscal 2022.

08:38 EST Flux Power expands testing, product validation capabilities - Flux Power announced the expansion of in-house testing and product validation capabilities with all equipment needed to satisfy UL 2580 and UN/DOT 38.3 compliance testing, including an onsite vibration table. Lithium-ion batteries with an Underwriters Laboratory, UL, Listing have been tested to meet nationally recognized safety standards as a complete final product, and also includes battery modules and battery packs. The UL 2580 battery test standard also tests the ability of batteries, battery modules and battery packs to withstand harsh conditions safely, testing whether they can be charged and discharged as required. UN/DOT 38.3 testing helps ensure the safety of lithium-ion batteries during shipping. "Our full suite of testing equipment is capable of in-house qualification on everything from our smallest to our largest battery systems, eliminating the need to outsource any aspect of testing for either UL or UN certifications and expediting the process," said Ron Dutt, Flux Power Chief Executive Officer. "Our strong relationship with Underwriters Laboratory coupled with these robust testing capabilities allows Flux Power to rapidly develop and deliver world-class energy storage systems to the critical applications of our end users. All Flux Power systems are designed and tested to meet the demanding standards of the modern operating environment with an unyielding focus on safety and reliability. We remain committed the delivery of clean energy solutions to this rapidly evolving market."

08:37 EST Paymentus unveils expanded cash bill payment capabilities network - Paymentus (PAY) unveiled expanded Cash Bill Pay capabilities on its Instant Payment Network. Powered by Green Dot Corporation's (GDOT) expansive Green Dot Network, billers connected to the Instant Payment Network will be able to accept cash payments from customers made at more than 90,000 retail locations. "Connecting the Green Dot Network of retail locations to our expanding Instant Payment Network demonstrates the transformative potential of our networked approach and our commitment to meet the payment service requirements of all consumers," said Dushyant Sharma, Founder and CEO of Paymentus. "Every biller knows that cash payments account for a meaningful portion of revenue. Untethering cash payments from the customer service counter and into tens of thousands of community-based access points will make cash bill pay as easy, convenient and secure as every other payment method for both consumers and billers alike."

08:37 EST Irish Data Protection Commission fines WhatsApp Ireland EUR 5.5M - The Data Protection Commission announced the conclusion of an inquiry into the processing carried out by WhatsApp Ireland Limited in connection with the delivery of its WhatsApp service, in which it has fined WhatsApp Ireland EUR 5.5M for breaches of the GDPR relating to its service. WhatsApp Ireland has also been directed to bring its data processing operations into compliance within a period of six months. The inquiry concerned a complaint made on May 25, 2018 by a German data subject about the WhatsApp service.

08:36 EST Outlook Therapeutics appoints Surendra Sharma as SVP, medical affairs - Outlook Therapeutics announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence. Most recently, Sharma was Senior Medical Director, Cornea, Dry Eye and Retina, Global Medical Affairs at Santen Pharmaceuticals. Prior to joining Outlook Therapeutics, in his role as the VP of Business and New Product Development at Fagron Sterile Services,Olsheim focused on driving revenue, profit and value in repackaging IV bevacizumab for ophthalmic use in retina indications.

08:35 EST Imax and Aeon Entertainment expand partnership in Japan - Imax and Aeon Entertainment announced an agreement for seven new Imax with Laser systems across Japan this year. Under the deal, all seven systems are scheduled to be installed in existing multiplexes by summer 2023 in areas largely untapped by Imax. The new expansion follows on the heels of an agreement Aeon and Imax announced at CinemaCon in April 2022 for two new locations outside Tokyo and Osaka. Japan was Imax's third highest grossing global market in 2022 with more than $73M in box office and home to six of the company's top 15 highest grossing locations. Imax earned a record $40.2M in global box office with Japanese language releases in 2022 - up 26% over 2021.

08:34 EST DTE Energy reduces Gas Cost Recovery rate - DTE Energy's natural gas customers will spend less to heat their homes this month, with further price reductions in the months to come. On Jan. 1, the company reduced its Gas Cost Recovery rate, based on its natural gas purchasing strategy and the decline in natural gas prices. The result? Customers will see a total of nearly $5 million in relief on their February heating bills. Further savings will come over the next several months as DTE expects to continue lowering its GCR rate.

08:33 EST Bigg Digital Assets' Netcoins announces further U.S. launch dates - BIGG Digital Assets reports that Netcoins will be expanding its USA footprint on February 1st, launching in Colorado, Kentucky, Kansas and Utah. The addition of these 4 states comes after the initial launch of Netcoins USA in California, Missouri, Virginia, Michigan and Pennsylvania in December 2022. The combined population of these nine states is over 93 million, which provides Netcoins with a tremendous opportunity for growth. Netcoins will also be adding Instant ACH funding to the Netcoins USA platform, integrating with Plaid and Sardine, two leading FinTechs with an established presence in the Crypto industry. Lastly, Netcoins will be launching three new crypto-assets on the Netcoins USA and Canada platforms. Netcoins is very pleased to add NEAR Protocol, QUANT and Cosmos. Netcoins is excited to bring these crypto-assets to our users in both Canada and the USA, bringing its overall offering to 38 coins.

08:32 EST Triumph Group awarded two multi-year contracts from Airbus - Triumph Group's (TGI) Actuation Products & Services business has been awarded two multi-year contracts from Airbus (EADSY). These contracts include the manufacturing of ball bearing control cables for the Airbus A330, A320 and A350 aircraft fleets.

08:32 EST Labrador Gold announces results from Florence Lake Greenstone Blt - Labrador Gold is pleased to announce results of prospecting and channel sampling at the Florence Lake Greenstone Belt on its Hopedale Project in Labrador. Highlights of the exploration include high-grade copper and gold in rock from both grab and channel samples from the northernmost license. Previous work by LabGold and others in this area has outlined significant gold in rock and soil over a 3km strike length, including four discrete mineralized occurrences: Thurber North up to 3.8 g/t Au; TD500 up to 21.59 g/t Au; Thurber Dog up to 11.4 g/t Au; Thurber South up to 4.1 g/t Au. Follow up sampling at the TD500 gold occurrence returned gold values from grab samples ranging from 0.46 g/t to 21.59 g/t Au. The showing was channel sampled along eight channels over a strike length of approximately 60 metres. Gold varies from below detection limit to 14.02 g/t with 48 samples assaying greater than 100ppb Au that includes 19 samples greater than 1 g/t Au. Highlights of the channel samples include 2.91 g/t Au over 5.17m including 14.02 g/t over 0.61m, 2.35 g/t Au over 6.88m and 4.23 g/t over 5.04m. Shear hosted gold mineralization at TD500 has now been uncovered over a 35m strike length and occurs in quartz veins and disseminated in the host rocks close to the contact between mafic volcanic and metasedimentary rocks. Pyrite and arsenopyrite are commonly associated with the gold mineralization. Grab samples from the copper occurrence ranged from 131 ppm to 10.2% Cu, with seven of the nine samples assaying over 1% Cu. Elevated silver in these samples ranged from 0.2 to 9.8 g/t Ag. The showing was channel sampled along eight channels over a strike length of approximately 50 metres. Results showed copper values ranging from 18ppm to 3.31% and silver values from 0.1 to 2 g/t. Highlights include 3.31% Cu over 0.76m, 2.4% Cu over 0.6m and 1.55% Cu over 1m.

08:31 EST Nautilus debuts JRNY with Motion Tracking - Nautilus is enhancing the JRNY app with Motion Tracking to jump-start those health and wellness goals. "Where other products in the market require single-purpose screens or devices, the JRNY app with Motion Tracking offers personalized coaching and feedback, rep counting and individualized workout recommendations using the tablet you already own, for a combination of features and convenience that's raising the bar for connected fitness," said Jim Barr, CEO, Nautilus, Inc. "The JRNY app leverages proprietary technology and machine learning expertise from our acquisition of VAY and positions Bowflex as an innovator in the strength training category. These enhancements to the JRNY platform mark an important milestone for Nautilus in our long-term strategy to provide a superior, consumer-driven connected fitness experience."

08:29 EST Otonomo and Iteris in intelligence deal to integrate connected vehicle data - Otonomo Technologies (OTMO), the platform powering the mobility economy, and Iteris (ITI) announced a multi-year agreement to integrate connected vehicle data available through the Otonomo Smart Mobility Data Platform into Iteris' ClearMobility Platform. This additional data source will help Iteris unlock new mobility insights from its multiple sources of traffic intelligence, advance its digital mobility infrastructure solutions for the public sector and commercial enterprise customers, and deliver on its mission of creating a future of smarter and connected transportation.

08:28 EST Nice announces Yource successfully employed its WFM solution - NICE announced that Yource, the leading business process outsourcer in the Netherlands, successfully employed NICE's Workforce Management, WFM, solution to further support the transition to a hybrid work model. Yource has seen an increase in forecast accuracy, ensuring more effective service and improving customer satisfaction. As a major omnichannel and multilingual contact center services provider, Yource provides a combination of outsourcing, insourcing, near and offshoring, and staffing options from its locations in the Netherlands, Belgium, Luxembourg, Spain, Morocco, Bulgaria, Greece, Turkey, and Suriname. NICE WFM improves forecast accuracy with AI-driven insights into net staffing fluctuations and schedule optimization. The solution automatically balances employee preferences and the company's business needs, making it a key element in a large-scale initiative at Yource to provide employees greater flexibility and control over their scheduling processes with the shift to hybrid work

08:27 EST Enviva announces four senior officer appointments - Enviva announced the appointments of a Chief Commercial Officer, Chief Sustainability Officer, Chief Administrative and People Officer, and General Counsel. Enviva has appointed John-Paul Taylor to Chief Commercial Officer. Taylor joined Enviva as Vice President, Optimization and Origination in February 2014 and most recently served as Senior Vice President of Sales and Fulfillment. Enviva has appointed Brandi Colander as Chief Sustainability Officer to maintain and enhance its role as an industry leader in sustainability and environmental stewardship. This function operates as an integral strategic partner throughout the Enviva enterprise. Additionally, Enviva has announced the appointment of Roxanne Klein to Chief Administrative and People Officer. In her new role, she will assume responsibility for a variety of corporate and administrative functions in addition to overseeing the human resources function. Finally, Jason Paral has been appointed General Counsel and will maintain his role as Secretary. Throughout his tenure at Enviva, Paral has held positions of increasing responsibility and closely supported the other members of the executive team and board of directors

08:25 EST Capstone Green Energy receives follow-on EaaS rental order - Capstone Green Energy announced that Horizon Power Systems, the company's exclusive Distributor for the Rocky Mountains in the U.S. and Western Canada, has secured an Energy as a Service, EaaS, long-term rental agreement for 30 Capstone C65 microturbines to be installed at 15 new and remote well sites throughout the San Juan Basin in New Mexico. The EaaS contract from this midstream oil and gas company adds to the customer's current owned fleet of 45 microturbines in operation, the first of which were commissioned in 2015. The new energy systems feature two high pressure natural gas-fueled microturbines per site and will provide power to Lease Automatic Custody Transfer units, which are used to transport crude oil from the production site to a central storage facility. "In addition to providing ultra-reliability to these typically remote, unmanned sites, microturbines have the added benefit of producing very low emissions," said Darren Jamison, Chief Executive Officer of Capstone Green Energy. "Now that several states are starting to require oil and gas companies to make emissions reductions, microturbines are proving to be an attractive option. Add to that the Capstone's flexible own or Energy as a Service options, and they become an ideal solution to modern energy challenges."

08:23 EST Falco Resources publishes ESG report - Falco Resources announced the release of its Environmental, Social and Governance report detailing the ESG performance of its activities for the period ending December 31, 2021. Helene Cartier, Vice President, Environment and Sustainable Development for Falco commented: "Falco has prioritized ESG factors to define its mission and has adopted an inspiring vision firmly rooted in its values such as transparency, integrity, determination and collaboration and which is reflected in our meaningful relationships with Indigenous nations, community members, and other groups. Falco is determined to build a lasting legacy everyday, through every action it takes and as we continue to evolve and grow, so will our dedication to our stakeholders."

08:22 EST Worksport to inspect major factory equipment for U.S. facility - Worksport announced the inspection of its commissioned custom manufacturing line. The assessment will take place by an agent of Worksport in Europe from Today January 19th to the 21st. The custom-made manufacturing line is essential to Worksport beginning and expanding automated production of its American-made hard folding truck covers. This manufacturing line will also produce components for Worksport's SOLIS solar truck bed cover system. The $4M custom manufacturing system is intended to automate the Company's in-house production of major components for Worksport's hard-fold tonneau covers, the basis for the much anticipated, highly innovative SOLIS solar truck bed cover. Once operational, the New York factory will be used to produce Worksport's proprietary hard tonneau covers. These products comprise the basis for SOLIS Solar Cover, expected to be the largest source of Worksport's future growth and revenues - and which has interest from several major global automotive OEMs. A complete working SOLIS cover needs its companion COR battery with its advanced hot-swap technology to store and deploy its saved power for a myriad of uses.

08:21 EST Freeline publishes proof-of-concept data for FLT190 to treat Fabry disease - Freeline Therapeutics announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy. Fabry disease is a debilitating genetic disorder in which an enzyme deficiency leads to a harmful build-up of fat in the cells that causes progressive organ damage and can result in early death."People living with Fabry disease can experience debilitating symptoms and disease progression, even with current treatments. There is a pressing need for therapies with more lasting efficacy that are less burdensome on Fabry families," said Pamela Foulds, M.D., Chief Medical Officer at Freeline. "We are encouraged by these preclinical data that support our ongoing Phase 1/2 clinical trial of FLT190 and our belief in FLT190 as a potential life-changing, one-time therapy for people with Fabry disease."

08:19 EST Natera announces new data on MRD test to be presented at ASCO GI 2023 - Natera announced that new data on its personalized and tumor-informed molecular residual disease, MRD, test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Symposium, ASCO GI, taking place January 19 - 21, 2023 in San Francisco, California. The presentations will highlight findings on the utility of Signatera for MRD assessment in colorectal, esophageal, gastric and anal cancers, in a total of five presentations. "On the heels of the groundbreaking CIRCULATE-Japan results just released, we are excited to share additional data further underscoring the real-world utility of Signatera in GI cancers," said Solomon Moshkevich, general manager of oncology at Natera. "This data continues to reinforce the value of personalized and tumor-informed MRD testing across different treatment settings." The preliminary findings from this study suggest that though cfDNA concentration is significantly increased in the first 2-4 weeks, Signatera detection rates remained consistent with those of weeks 4-8, indicating that standard MRD testing windows could start two weeks after surgery.

08:18 EST J&J, partners to discontinue Phase 3 Mosaico HIV vaccine clinical trial - The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, yesterday announced the results of an independent, scheduled data review of the Phase 3 Mosaico study of Janssen's investigational HIV vaccine regimen. The study's independent Data and Safety Monitoring Board, or DSMB, determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified. In light of the DSMB's determination, the Mosaico clinical trial will be discontinued. Participant notifications and further analyses of the data are underway. Throughout the trial, study investigators have ensured that any individuals who contracted HIV received prompt HIV treatment and care. "We are disappointed with this outcome and stand in solidarity with the people and communities vulnerable to and affected by HIV. Though there have been significant advances in prevention since the beginning of the global epidemic, 1.5 million people acquired HIV in 2021 alone, underscoring the high unmet need for new options and why we have long worked to tackle this global health challenge. We remain steadfast in our commitment to advancing innovation in HIV, and we hope the data from Mosaico will provide insights for future efforts to develop a safe and effective vaccine," said Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development. Reference Link

08:16 EST Energy Vault appoints Fariello to board of directors - Energy Vault (NRGV) announced the appointment of Theresa Fariello to the Company's Board of Directors effective February 1, 2023. She replaces Henry Elkus, Founder and CEO of Helena, a strategic partner and Series B-1 investor in Energy Vault, upon his concurrent departure from the Board. Fariello has served as Senior Vice President of Government Affairs & Global Public Policy for United Airlines (UAL) since 2017.

08:14 EST Medavail to exit pharmacy services, SpotRx, reduce staff by 75% - The company said, "MedAvail is exiting the pharmacy services and SpotRx business. While the business has opportunities for growth and the company demonstrated an ability to significantly scale its retail pharmacy operations, it is not aligned with the company's strategy to shorten its path to profitability. Based on the renewed focus on pharmacy technology and exit of pharmacy services, the company is reducing its staff by approximately 75 percent. The actions that are being undertaken by MedAvail are expected to result in annualized operating expense savings of $35 million to $37 million compared to the full year 2022. The company's business following the exit from the pharmacy services business will solely consist of its pharmacy technology business. Total sales for the pharmacy technology business in 2022 is expected to be in the range of $1.2 million to $1.4 million, which included a retail segment that will not be part of MedAvail's sales channel focus going forward. The company expects pharmacy technology to support strong growth in 2023 over 2022 with respect to this business. Further, pharmacy technology has historically attracted higher margins than the pharmacy services segment."

08:13 EST Medavail says pharmacy technology represents 'significant growth opportunity' - The company said, "MedAvail's pharmacy technology business represents a significant growth opportunity. Through this business, MedAvail offers customers the ability to purchase the MedCenter and to license MedAvail's software in order to provide point of prescription dispensing solutions under their own brands. This offering generates a profitable recurring revenue stream and favorable unit economics, such as a gross margin for 2022 that is expected to be greater than 45%. MedAvail's MedCenter technology platform enables remote medication dispensing through MedAvail's proprietary kiosks which are integrated into the customers' patient-care information systems. Patients interacting with these kiosks are able to consult virtually with a customer-employed pharmacist and to fill their prescriptions at the point of care through the MedCenter, eliminating the need to make a separate trip to a pharmacy. Increasing patient access to prescription medications with expert services at the point of prescribing contributes to increased patient satisfaction and addresses key barriers to medication adherence. The restructured company will focus on technology and pharmacy management integrations to support its substantial pipeline for new partnerships. The pharmacy technology business today addresses a large opportunity with urgent care sites, expanding patient access to quality pharmacy care and prescription medications quickly and efficiently, and the company is focused on broadening its footprint within this channel. MedAvail will also grow its technology business with value-based providers by leveraging its proven track record of adding significant value to value-based care providers with the former SpotRx business."

08:12 EST Medavail to focus on pharmacy technology, exit pharmacy services, SpotRx - MedAvail Holdings announced the execution of a strategic restructuring and reprioritization of its business targeted to deliver profitability. Following an extensive review of the market landscape, growth strategy and structure of the business, the company is taking actions and restructuring its organization to focus on its pharmacy technology business and exit its pharmacy services and SpotRx business. With respect to the pharmacy services and SpotRx business, the company has hired a broker and is in active negotiations regarding the sale of its pharmacy assets. These actions aim to significantly reduce headcount and cash burn, which position the company to achieve its goals of delivering profitable growth and positive cash flow sooner. In connection with the restructuring, the company is also evaluating multiple financing options, including with existing investors. "We believe that the critical steps we are taking to focus on our pharmacy technology business provide a clear roadmap to delivering profitable and sustainable growth and to maximizing value of the Pharmacy Tech business for our shareholders," said Mark Doerr, CEO of MedAvail.

08:10 EST Apexigen announces new data evaluating agonist antibody sotigalimab for CD40 - Apexigen announced the presentation of new data from Phase 2 multicenter clinical trials evaluating sotigalimab or sotiga , Apexigen's agonist antibody targeting CD40, in two poster presentations at the ASCO Gastrointestinal Cancers Symposium, being held both virtually and in San Francisco, California from January 19-21. "We are excited to present new data at ASCO demonstrating sotiga's differentiated mechanism of action and ability to expand anti-tumor immune responses by modulating the tumor microenvironment for increased therapeutic effect," said Frank Hsu, M.D., Chief Medical Officer of Apexigen. "In patients with esophageal/gastro-esophageal junction cancer, single-agent sotiga turned immunologically "cold" tumors "hot" by inducing significant inflammatory responses in the TME. Following a single dose of sotiga monotherapy there was an increase in T cell density, particularly activated and memory cytotoxic T cells and macrophages. Although patient sample numbers are small, pathologic complete responses were associated with an increased density of T cells following a single dose of sotiga. In a separate study, results demonstrated that adding sotiga to short-course radiation therapy (SCRT) led to increased activation of anti-cancer immune cells, including T cells, B cells and dendritic cells in the TME of rectal cancer patients compared to SCRT alone. We believe sotiga has the potential to provide meaningful clinical benefit across multiple solid tumor indications and become a backbone of combination therapy to address the need for innovative treatment options. We look forward to providing further updates as we advance our clinical program."

08:08 EST Innovative Industrial Properties reports Q4 activity, shares fall 13% - Last night, Innovative Industrial Properties announced: "Rent collection for IIP's operating portfolio was as follows: 92% collected as of today for the month ending January 31, 2023 (including approximately $324,000 of a security deposit applied for payment of rent for IIP's lease with Holistic Industries Inc. at IIP's Michigan property and receipt of the full rent payment from Sozo Health, Inc.; 94% collected for the three months ended December 31, 2022; and 97% collected for the year ended December 31, 2022. As of January 18, 2023: SH Parent was in default on its obligations to pay rent at one of IIP's Pennsylvania properties. Rent was paid in full through January 31, 2023 on all other IIP properties leased by Parallel. Green Peak Industries was in default on its obligations to pay rent at one of IIP's Michigan properties under construction. Rent was paid in full through January 31, 2023 on all other IIP properties leased by Skymint. Affiliates of Medical Investor Holdings were in default on their obligations to pay rent at IIP's California properties." Shares of Innovative Industrial Properties are down 13% in pre-market trading at $96.75.

08:08 EST Daxor joins Heart Failure Society of America as corporate member - Daxor Corporation announces joining the Heart Failure Society of America as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. "The HFSA is the premier society focused on improving Heart Failure outcomes, a condition that more than 6 million Americans suffer from - one of the most prevalent, complex, and deadly diseases leading to nearly 1 million deaths and 1 million hospitalizations annually," said Michael Feldschuh, CEO and President of Daxor Corporation. "We have been a long-time exhibitor at the HFSA annual meeting where valuable BVA research has been presented annually. Now as a corporate member, we have the opportunity to further advance our BVA-100 technology and strengthen our relationship with heart failure leaders to improve adoption of our products and better the lives of heart failure patients."

08:07 EST FDA accepts Intercept NDA for OCA to treat NASH pre-cirrhotic liver fibrosis - Intercept Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted Intercept's New Drug Application NDA for obeticholic acid OCA seeking accelerated approval for the treatment of patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis, NASH. FDA indicated that it considers this a complete, Class 2 resubmission and has assigned a Prescription Drug User Fee Act PDUFA target action date of June 22 for the NDA. The timeline for the review of the NDA by FDA remains subject to change. "This regulatory milestone brings us one step closer to reaching our goal of delivering the first available therapy for patients living with pre-cirrhotic fibrosis due to NASH - the most rapidly growing cause of liver transplantation in the U.S.," said Jerry Durso, President and Chief Executive Officer of Intercept. "We believe OCA has the potential to become an important therapy given its strong and direct antifibrotic effect, and we look forward to continuing our work with FDA over the coming months as they review our NDA."

08:06 EST LifeVantage announces LV360 transformation inititiatives - LifeVantage Corporation announced major transformation initiatives including Evolve, an innovative approach to Consultant compensation. LV360 initiatives were announced to Consultants during the Rock the Rhythm event on January 18, 2023. The event was simultaneously broadcast in the U.S., Australia, New Zealand, and Japan markets, to an audience of over 10,000. In addition to Evolve, LV360 initiatives include a new Customer loyalty program called Rewards Circle. Both Evolve and Rewards Circle are scheduled to launch in the U.S., Australia, New Zealand, and Japan on March 1, 2023. These initiatives are planned to roll out to other markets where LifeVantage products are sold and distributed over the next 12 months. New products, the Rise AM & Reset PM System and LifeVantage D3+, were also announced as the Company continues to advance its product innovation roadmap, building on the strong momentum from its recent introduction of Liquid Collagen. LV360 initiatives also include a revamped e-commerce experience as well as major enhancements to Account and Subscription management. Several new promotions and incentives will be rolling out in advance of the March 1st launch to help Consultants prepare for the exciting new opportunities that lie ahead. Over the coming weeks the Company will host over 50 roadshows and virtual training sessions globally aimed at developing rising, confident leaders, excited to share this cutting-edge opportunity with others. Regional Evolve events will also be held in March in the U.S., Australia, and Japan to continue field support and training of these new initiatives.

08:05 EST Grubhub partners with RapidSOS to enhance driver safety - Grubhub announced it is enhancing safety for its delivery partner community by linking into RapidSOS, the intelligent safety platform that routes life-saving data to first responders in an emergency. The partnership will provide Grubhub delivery partners the ability to share dynamic location data as well as caller ID (name, phone number) directly to 911 responders when an emergency call is placed via the Grubhub for Drivers App. The integration is now available in New York City, Boston, Philadelphia and Chicago and will roll out nationwide by mid-2023.

08:05 EST Cyngn appoints Chris Wright as Head of Sales - Cyngn announced the appointment of Chris Wright as Head of Sales. Wright has over 30 years of experience in sales, bringing a wealth of knowledge and industry expertise in both robotics and manufacturing. Chris Wright brings extensive experience and sales leadership in the robotics industry. Most notably, Wright served as Vice President of Sales from 2017 to 2022 at Brain Corp, a robotic AI software company that powers autonomous mobile robots for commercial, public spaces.

08:04 EST Purple Innovation special committee comments on Capital Management filing - Purple Innovation responded to the amended Schedule 13D filed with the SEC by Coliseum Capital on January 17. The statement by the Special Committee of the Board states, among other things: "The Special Committee values Coliseum's investment in Purple and shares Coliseum's enthusiasm for, and confidence in, the company's plan and management team. However, the Special Committee is disappointed that within days of the Special Committee rejecting Coliseum's inadequate and below-market buyout proposal, Coliseum is seeking to replace most of the Board...Coliseum's Managing Partner Adam Gray has served on the Board since the time that Purple went public in 2018...Coliseum's current proposal to reconstitute Purple's Board of Directors goes beyond what we consider appropriate: Coliseum is seeking the right to appoint, identify or approve every member of Purple's Board...We remain interested in working cooperatively with Coliseum, and we will continue to seek to do so while protecting the interests of all shareholders."

08:03 EST Live Ventures acquires Flooring Liquidators for $84M - Live Ventures has acquired the outstanding equity interests of Flooring Liquidators, a retailer and installer of floors, carpets, and countertops to consumers, builders and contractors in California and Nevada. The transaction, valued at approximately $84M, was financed through a combination of cash, debt, including a $5M note from Isaac Capital Group, and the issuance of 116,441 shares of our common stock, representing a 3.78% dilution of Live Ventures' fully diluted common stock. As part of the acquisition, Live Ventures will retain Flooring Liquidators' existing management team and all 625 employees and contractors. As part of the transaction, Live Ventures also acquired Floorable, LLC, the company's franchise opportunity utilizing proprietary in-home shopping mobile showrooms and an established back-office support system along with K2L Leasing, LLC and SJ &K Equipment, Inc.

08:02 EST Roblox falls 7% to $33.33 in pre-market after Morgan Stanley downgrade

07:57 EST Bowlero CEO sells $1.0M in common stock - In a regulatory filing, Bowlero disclosed that its CEO Thomas Shannon sold 71K shares of common stock on January 13th in a total transaction size of $1.0M.

07:47 EST Asante Gold reports December consolidated gold production of 24,180 ounces - Asante Gold Corporation announces a 20.7% increase in average monthly gold production for November and December 2022, as compared with the prior two months, from its Bibiani Gold Mine and Chirano Gold Mine in Ghana. Highlights: Continued its record of no lost time from injuries; Consolidated preliminary gold production of 23,760 and 24,180 ounces respectively for November and December; Completed final $30M deferred payment, completing the Bibiani acquisition; Completed ~$54M in first and second tranche payments on the Company's gold forward sale agreement in October 2022 and January 2023 through the delivery of 16,249.60 and 14,113.51 ounces of gold, respectively; Captured more than C$1.5M in cost reductions out of previously reported potential synergies between Chirano and Bibiani of approximately C$5.5M to $7M per year; Continued exploration at Bibiani and Chirano, targeting increased in mine life; Near mine exploration programs have reported significant success at South Russel and Aboduabo; The Chirano business improvement plan is advanced, targeting a 30% increase in production and a 10% decrease in AISC for calendar 2024; Bibiani ramp up on track with ~230,000 tonnes of ore processed in each of November and December, approximately 18% above plan; Chirano is achieving target production levels with ~285,000 tonnes of ore processed in December, up 7.5% from ~265,000 tonnes in November; Bibiani and Chirano have combined forecast production of approximately 400,000 ounces of gold for 2023. Dave Anthony, President and CEO, stated, "Over the past 12 months Asante has been transformed from an early-stage exploration company to a mid-tier gold producer. The significant production gains in November and December bode well for the achievement of our 400,000 ounce target from Bibiani and Chirano for the fiscal year ending January 31, 2024. Over the past five months we have made payments totaling $83.6M towards closing our Bibiani acquisition and repaying our gold forward sale agreement. Looking forward, we continue to capture the benefits of owning these two nearby operating mines, which incorporate a district scale land package with significant exploration potential. Value creation initiatives are proceeding across our business as we look to make Asante one of the top mining companies in Africa."

07:38 EST Pressure BioSciences reports results from focus group testing of THC Oral Spray - Pressure BioSciences announced results from initial consumer focus group testing of a THC Nanoemulsion Oral Spray prepared using PBI's revolutionary Ultra Shear Technology platform. Preparation of the THC Nanoemulsion Oral Spray was completed by PBI's California-based partner companies, including Creme De Canna, a CA-licensed manufacturer. John Hollister, PBI's Director of Sales and Marketing, explained: "Cannabinoids like THC are oil-soluble molecules that are typically poorly absorbed when ingested by our water-based human bodies. For THC edibles, most consumers report waiting 30-60 minutes for first effects and 60-90 minutes to peak effects. Impatient consumers may repeatedly consume their edibles, only to be unhappily over-dosed two hours later. Conversely, smoking and vaping produce first effects immediately and peak effects quickly but are increasingly in disfavor for the well-known respiratory health consequences that accumulate. PBI's partners in California used our revolutionary UltraShear platform to prepare extreme nanoemulsions of THC into an Oral Spray for consumer testing. Multiple test groups have confirmed that the UltraShear Nanoemulsion THC Oral Spray produces first effects between 1-10 minutes, often in the first 1-5 minutes, with peak effects reached in 15-60 minutes, often within 15-30 minutes. This testing has provided dramatic consumer-level validation in the cannabis market for our UltraShear nanoemulsion capabilities and for its expected market-changing impact. We are anticipating substantial revenues from the first THC UltraShear Nanoemulsion Oral Spray to be marketed by our California partners, beginning in this quarter."

07:33 EST Sunshine Biopharma announces $2M stock repurchase program - Sunshine Biopharma announced its board of directors has authorized a share repurchase program to acquire up to $2M of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. As of September 30 the Company had approximately $40.5M of cash and cash equivalents. The Company had approximately 22.6M shares of common stock issued and outstanding as of November 7.

07:32 EST Palatin begins enrollment in Phase 2 study of diabetic kidney disease candidate - Palatin announced the initiation of a Phase 2b clinical trial with the melanocortin agonist, bremelanotide. The BREAKOUT Study initiated patient screening/enrollment in December 2022, and currently expects to initiate patient dosing in January 2023. The study is designed to enroll up to 45 subjects, with biopsy-proven type II diabetic kidney disease and greater than1000 mg/gm UP/Cr ratio. The primary endpoint of the study is a 50% reduction in their urine protein/creatinine ratio after six months of combined therapy. Secondary endpoints include analyses of partial remission, clinical remission and change in eGFR. Based on current enrollment estimates, the BREAKOUT Study is expected to complete enrollment in 3Q23, with final topline data by end of 1Q24.

07:17 EST Veris Residential shareholder Kushner responds to Veris Board statement - Veris Residential shareholder Kushner sent a response to Veris' Board of Directors following their update on discussions with Kushner Companies: The press release states, among other things: "...Despite Veris' repeated efforts to cast doubt on the credibility of our proposals, for the past several months Kushner has sought to work collaboratively with Veris. During this period, we have raised our offer price on multiple occasions, yet at no point has Veris provided any counterproposal, nor indicated a range of values at which it would be prepared to transact..Our financing partners, which the Board and its advisors know very well and have worked with extensively, forcefully reiterated their full commitment to the financing of our bid...Since that day, Kushner and its financing partners have worked diligently to finalize a potential confidentiality and standstill agreement with Veris that would provide us access to non-public information...After the January 13 video conference, a significant Veris shareholder filed a 13D amendment, disclosing that on January 12 that shareholder had met with the Veris nominating and corporate governance committee and requested representation on the Veris board...Since learning of that SEC filing, we have been evaluating the implications of this development. We have expressed to Veris on multiple occasions that we were continuing to assess the impact of this development before deciding on next steps. ..The actions taken by the Veris board today eroded shareholder value, with the stock plummeting to below $15.00 in after hours trading, and reinforced our longstanding concern that the Veris board is entrenched, and does not want to engage in good faith in discussions regarding a transaction that would result in a loss of its-and its chosen high-priced management team's-perks. Meanwhile, the Veris board has permitted insider share purchases and made new equity grants, despite being engaged in M&A discussions. Veris shareholders deserve a Board that recognizes its responsibilities, acts on its words, and engages in serious and transparent processes to achieve value for its shareholders. Unfortunately, Veris' current Board has shown neither the ability nor the willingness to so engage".

07:13 EST Complexity Gaming renews partnership with Miller Lite - GameSquare Esports (GMSQF) announced that Complexity Gaming has renewed its partnership with Miller Lite (TAP) for the fourth consecutive year, reflecting the power of Complexity's brand within the esports market, and Miller Lite's commitment to supporting the gaming community and culture.

07:12 EST Lifeist's Cannmart to introduces multi-pack cannabis products in Ontario - Lifeist Wellness announced that its wholly owned Canadian cannabis business unit CannMart has leveraged market research and consumer insights to introduce several higher margin multi-pack offerings in Ontario through the Ontario Cannabis Store that are believed to be first-to-market in the province. CannMart made its multi-pack entrance into Ontario with the Roilty Shatter Pack: Catacomb Kush 0.5G & The Mountain Kush 0.5G, featuring two shatters from Roilty in one package. As momentum grows on this format, the OCS has decided to list a second shatter multi-pack, Roilty Shatter Pack: The Mountain Kush 0.5G & Purple Dream. The new offering will be available in April 2023 via the OCS's Flow-Through Channel, which allows retailers to purchase products not listed on the OCS website for consumers, to further curate and differentiate their stores' product offerings. Additionally, the OCS has listed three General List Roilty multi-packs SKUs in the live resin, diamonds, and vape cart categories.

07:09 EST Verano Holdings announces opening of MUV Navarre - Verano Holdings announced the opening of MUV Navarre on Friday, January 20, the Company's 63rd Florida dispensary and 121st nationwide. MUV Navarre, located at 6863 Navarre Parkway, is open Monday through Saturday from 9 a.m. to 5 p.m. and Sunday from 11 a.m. to 5 p.m., local time.

07:08 EST Repare Therapeutics receives $1.5M payment from Ono Pharmaceuticals - Repare Therapeutics (RPTX) announced that the Company has received an approximately $1.5 M research service payment from Ono Pharmaceutical (OPHLY). The payment reflects achievement of a specified research trigger, under the companies' 2019 Strategic Partnership Agreement. Under the terms of the Ono Agreement, Repare is primarily responsible for carrying out research activities for its Pol program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan. "This reflects an important milestone in our RP-2119 Pol program, as we undertake our IND-enabling studies and prepare for our previously guided initiation of clinical trials in the summer of 2023," said Kim Seth, Chief Business Officer of Repare.

07:08 EST HF Foods Group appoints Prudence Kuai to board of directors - HF Foods Group has appointed Prudence Kuai, a 25-year veteran of the healthcare industry and a thought leader in applying technological advancements in operational process automation, eCommerce, utilization of artificial intelligence and data analytics, to the Company's board of directors effective January 17. As a result of Ms. Kuai's appointment, the Company's board of directors will now include four independent directors and Mr. Peter Zhang, the CEO of the Company.

07:07 EST Alpine Beer launches INFINITE HAZE IPA - Alpine Beer announces the release of Infinite Haze, a Hazy IPA bursting with endless aromas of citrus and sweet, tropical fruits. Infinite Haze is the newest addition to Alpine's year-round lineup and is available now in 12-ounce cans in California, with plans for national distribution in 2023.

07:06 EST Amarin calls Sarissa statement 'inaccurate and misleading' - Amarin issued a statement in response to Sarissa Capital Management, which read in part, "Sarissa is tapping into shareholder frustration but not providing any answers or plans. How specifically does Sarissa plan to increase shareholder value? Contrary to Sarissa's misrepresentation of the facts, the Amarin Board of Directors' refreshment process has been comprehensive, independent and transparent. The Board engaged a leading independent search firm in October 2021 which identified each of the six new independent directors who have joined the Board in the last year. Throughout this process, the Board considered upwards of 30 candidates against clear selection criteria with critical skillsets needed to oversee Amarin's transformation plan including: international commercial experience, global pharma partnerships and M&A, pricing and reimbursement, finance and healthcare investment, clinical development and corporate governance. Amarin takes its Board refreshment process seriously and will not circumvent any step at the demand of one shareholder. The Board interviewed three of Sarissa's five proposed candidates, all of whom are Sarissa employees, alongside independent candidates the Board had identified. In addition, Sarissa demanded that at least three of their candidates be appointed in a matter of days after the names were finally shared with the Company. Of note, two of Sarissa's original five proposed candidates were junior Sarissa research analysts with less than five years of work experience. Throughout our engagement and during the interviews with their candidates, Sarissa never proposed a single idea to help advance the business. With no plan and no new ideas, Sarissa is not the answer. Sarissa is now putting forward seven underqualified candidates, three of whom are Sarissa employees, who collectively lack critical understanding of operating a commercial stage company and have minimal experience with European product launch, pricing and reimbursement and commercial expertise...With Amarin at a strategic inflection point, we believe Sarissa's misguided proxy contest will create significant disruption to the Company's efforts in driving positive pricing and reimbursement decisions in Europe, continued stabilization of the U.S. business, advancement of our international strategy and progress on our FDC program."

07:04 EST Broadwind confirms receipt of notice from WM Argyle Fund - Broadwind confirmed receipt of notice from WM Argyle Fund , which allegedly owns approximately 1.0% of the Company's outstanding common stock valued at approximately $1.2M of its purported intent to nominate six individuals for election to the Company's Board of Directors at the Company's 2023 annual meeting of stockholders. The Board will consider the Fund's proposed nominees in due course and review the Fund's notice for compliance with its established procedures under the Company's bylaws and applicable law. The Board will present its recommendations in the Company's definitive proxy statement, which will be filed with the Securities and Exchange Commission and made available to all stockholders entitled to vote at the 2023 Annual Meeting. The Company has engaged with the Fund, as it would with any stockholder, and is disappointed that the Fund has chosen to initiate a costly and disruptive proxy contest, particularly given the Company's recent track record of value creation. Broadwind believes that the Fund's attempt to take over Broadwind's full Board represents a disguised attempt to seize control of the Company without paying a premium. However, Broadwind remains committed to maintaining an open dialogue while continuing to represent the best interests of all stockholders.

07:03 EST Teva announces targets to reduce GHG emissions approved by SBTi - Teva Pharmaceutical Industries announced that its targets to reduce greenhouse gas, GHG, emissions have been approved by the Science Based Targets initiative, SBTi, providing external validation of the Company's ambitious commitments to minimize its environmental footprint. The targets validated by SBTi are to reduce absolute scope 1 and 2 GHG emissions by 46% by 2030, aligning to a 1.5 degrees C pathway, and reducing absolute scope 3 GHG emissions by 25% by 2030, aligning to a well-below 2 degrees C pathway.

07:02 EST SaverOne 2014's safe driving system adopted by Israeli supermarket Shufersal - SaverOne 2014 announced that Shufersal, Israel's retail food chain, has installed the SaverOne system on part of its fleet of large food delivery trucks, which handle food delivery between its logistic centers. In the first phase which is a trial phase, the installation of the SaverOne System was completed on a group of 19 large delivery trucks out of the Shufersal truck fleet of 150. Furthermore, there is potential for further installations beyond this fleet, as Shufersal operates a further fleet of a few hundred smaller trucks for the delivery of food to the home. SaverOne's technology recognizes the driver area in the vehicle and prevents the driver from accessing distracting applications such as messaging, while allowing others such as navigation, without user intervention or consent, aiming to create a safer driving environment.

07:01 EST Palantir, Cleveland Clinic partner to improve hospital performance - Palantir Technologies and Cleveland Clinic announced a multi-year partnership to deliver an operations "Virtual Command Center" for Cleveland Clinic. The Virtual Command Center brings an innovative approach to driving operational excellence and improving patient access by enabling data-driven decision making and resource allocation on hospital frontlines.

06:59 EST Comerica sees Q1 average loans up over 1% vs. Q4 - Sees average deposits down 3%. Sees net interest income down 3%-6% with NIM 3.75%-3.85%. Sees noninterest income down 5% and noninterest expense down 3%-4%.

06:58 EST Procter & Gamble CEO says 'very difficult cost and operating environment' - "We delivered solid results in the second quarter of fiscal year 2023 in what continues to be a very difficult cost and operating environment," said Jon Moeller, Chairman of the Board, President and CEO. "Progress against our plan fiscal year to date enables us to raise our sales growth outlook for fiscal 2023 and maintain our guidance range for EPS growth despite significant headwinds. We remain committed to our integrated strategies of a focused product portfolio, superiority, productivity, constructive disruption and an agile and accountable organization structure. These strategies have enabled us to build and sustain strong momentum. They remain the right strategies to navigate through the near-term challenges we're facing and continue to deliver balanced growth and value creation."

06:57 EST Comerica sees 2023 average loans up 7%-8% vs. 2022 - Average loans +7 to 8% with growth in most businesses; Average deposits -7 to -8% as customers continue to utilize excess liquidity; Net interest income +17 to 20% reflecting net benefit from higher rates & loan growth; Credit Quality NCOs move toward lower end of normal range & continue to modestly build reserves; Noninterest income +5% with higher risk management income, card & fiduciary; partly offset by lower derivative income, deposit service charges & BOLI; assumes CVA & deferred comp do not repeat; Noninterest expenses +7% with pension up, assuming deferred comp does not repeat & lower modernization and +4% excluding pension & modernization, assuming deferred comp does not repeat; Tax FY tax rate ~23%, excluding discrete items; Capital Target CET1 of ~10%. Comments taken from Q4 conference call slides.

06:54 EST KeyCorp sees FY23 NII up 6%-9%, noninterest income down 1%-3% - Sees Fy23 loans up 6%-9%, with deposits flat to down 2%, and relatively stable noninterest expense. Sees a GAAP tax rate of 19%-20%.

06:53 EST NRx Pharmaceuticals reaches alignment with FDA on manufacturing plan - NRx Pharmaceuticals announced that it had a meeting and a written response from the Food and Drug Administration last week regarding its lead compound, NRX-101. In response to a request for Type C guidance on the chemistry, manufacturing and controls aspects of the NRX-101 program, FDA provided Written Responses on January 10th. As previously announced in October 2022, an updated NRX-101 module 3 was submitted to add the intended commercial manufacturer to the IND. With FDA's written response, it appears that NRx Pharmaceuticals has reached alignment with the FDA regarding its proposed registration manufacturing plan. A Type B meeting with the FDA was held on January 11, 2023. Minutes of the meeting are expected to be available in approximately 30 days.

06:52 EST Fifth Third sees Q1 total revenue down 4%-5% vs. 4Q22, consensus $2.29B - Sees Q1 net interest income down 1%-2% vs. 4Q22, with noninterest income down 11%-13% and average loans and leases stable. Sees Q1 noninterest expense up 6%-7%, with net charge-off ratio 25-30bps and an effective tax rate of roughly 23%.

06:51 EST Tenet Healthcare CFO Daniel Cancelmi retiring at year-end - Tenet announced leadership updates and operational organizational changes, including the retirement of Daniel Cancelmi, Executive VP & CFO, at the end of 2023. A national search is ongoing to identify a high performing successor. The retirement of Brett Brodnax, President & CEO of USPI, at the end of 2023 was also announced. Additionally, Andy Johnston has returned to USPI as its Chief Administrative Officer. He is anticipated to be promoted once Brodnax steps down. Brodnax has also offered ongoing support in a non-management role after the end of 2023. The announcement also included the retirement of Roger Davis, President & CEO of Conifer Health Solutions, at the end of 1Q23. A national search is in progress. Deepali Narula has been promoted to COO of Conifer. Deepali was previously Senior VP, HRCM Operations. Bryan Forry has been promoted to CFO of Conifer. Bryan was previously Controller, Hospital Operations and prior to that led performance management innovation, as well as CFO for Tenet's Arizona operations.

06:41 EST Toronto-Dominion comments on expected impact of Charles Schwab's Q4 earnings - TD Bank Group (TD) announced that it expects The Charles Schwab Corporation's (SCHW) fourth quarter earnings to translate into approximately C$285M of reported equity in net income of an investment in Schwab for the Bank's fiscal 2023 first quarter. Excluding acquisition-related charges of approximately C$13M after-tax and amortization of acquired intangibles of approximately C$30M after-tax, adjusted equity in net income of an investment in Schwab will be approximately C$328M. TD Bank Group will release its first quarter financial results and host an earnings conference call on March 2.

06:02 EST Global Net Lease acquires eight UK properties for GBP 61M - Global Net Lease (GNL) closed on the acquisition of eight properties in the United Kingdom for a total purchase price of GBP 61M at a cap rate of 10.6%. The properties are all leased to a wholly owned subsidiary of Walgreens Boots Alliance (WBA). Walgreens has investment grade credit ratings of "BBB" and "Baa2" from S&P and Moody's, respectively. The properties total over 325,000 square feet and have 11.5 years of lease term remaining. Additionally, GNL announced that on December 30, 2022, it was notified by Rheinmetall (RNMBY) that a five-year lease extension was exercised, extending the tenant's lease on the existing terms until the end of 2028 with no tenant improvement expenses incurred by the Company. Rheinmetall is rated "Baa2" by Moody's. Including this lease, the Company completed 592,000 square feet of new leases, lease renewals, and tenant expansions in the fourth quarter of 2022.

05:42 EST Amazon to wind down AmazonSmile by February 20 - Amazon, in an email to AmazonSmile customers, said: "In 2013, we launched AmazonSmile to make it easier for customers to support their favorite charities. However, after almost a decade, the program has not grown to create the impact that we had originally hoped. With so many eligible organizations-more than 1 million globally-our ability to have an impact was often spread too thin. We are writing to let you know that we plan to wind down AmazonSmile by February 20, 2023. We will continue to pursue and invest in other areas where we've seen we can make meaningful change-from building affordable housing to providing access to computer science education for students in underserved communities to using our logistics infrastructure and technology to assist broad communities impacted by natural disasters. To help charities that have been a part of the AmazonSmile program with this transition, we will be providing them with a one-time donation equivalent to three months of what they earned in 2022 through the program, and they will also be able to accrue additional donations until the program officially closes in February. Once AmazonSmile closes, charities will still be able to seek support from Amazon customers by creating their own wish lists. As a company, we will continue supporting a wide range of other programs that help thousands of charities and communities across the U.S."